<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01072175</url>
  </required_header>
  <id_info>
    <org_study_id>113220</org_study_id>
    <nct_id>NCT01072175</nct_id>
  </id_info>
  <brief_title>Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 &amp; GSK1120212</brief_title>
  <official_title>An Open-Label, Dose-Escalation, Phase I/II Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of the BRAF Inhibitor GSK2118436 in Combination With the MEK Inhibitor GSK1120212 in Subjects With BRAF Mutant Metastatic Melanoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was an open-label, dose escalation study to investigate the safety, pharmacokinetics,
      pharmacodynamics and clinical activity of GSK2118436 and GSK1120212 in combination. This
      study was designed in four parts. In Part A, the effect of repeat doses of GSK1120212 on the
      pharmacokinetics of single dose GSK2118436 was investigated prior to evaluating combination
      regimens. In Part B, the range of tolerated dose combinations was identified using a
      dose-escalation procedure. In Part C, different dose combinations of GSK2118436 and
      GSK1120212 were evaluated, based on results from the dose escalation cohorts. In Part D, the
      pharmacokinetics and safety of GSK2118436 administered as HPMC capsules alone and in
      combination with GSK1120212 was evaluated.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During Part A, a cohort of subjects received a single dose of GSK2118436 alone (Day 1) and
      then repeat doses of GSK1120212 for (Day 2 through Day 15). The dose regimen of GSK1120212
      were continuous dosing. A second single dose of GSK2118436 was administered on Day 15
      concomitantly with GSK1120212. Day 16 through Day 28 was a washout period, during which no
      study medication was administered. Starting on Day 29, subjects who elected to continue
      participation in the study were doses with GSK2118436. The dose of GSK2118436 after Day 29
      might be altered based on emerging data from the first-time-in human study BRF112680. The
      dose might be increased to a dose level that has been completed and determined to be less
      than or equal to the maximum tolerated dose in that study.

      Part B of the study enrolled cohorts in escalating doses to identify a set of allowable doses
      to be expanded in Part C. Subjects were enrolled in a 3+3 cohort design, with provisional
      dose levels of both drugs. The decision regarding escalation to the next dose levels of
      GSK1120212 and GSK2118436 was further guided by a Bayesian logistic regression model. The
      first cohort started at low doses for both drugs. Doses up to 300 mg/day for GSK2118436 and
      up to 3 mg QD for GSK1120212 were studied. The starting dose might be lowered based on
      emerging data from other studies and from Part A.

      Expansion cohorts enrolled in Part C at dose levels of GSK2118436 and GSK1120212 as defined
      in Part B. One of the selected doses might include GSK2118436 administered as monotherapy at
      a tolerable dose (less than or equal to the maximum tolerated dose) determined in BRF112680.
      Part C was a randomized open-label Phase II portion of the study, and consisted of expansion
      cohorts investigating 2 to 3 dose levels of GSK2118436 and GSK1120212 dosing in combination,
      and GSK2118436 administered as monotherapy. Subjects were assigned to treatment arms in a
      randomized fashion to compare tolerability and safety. Population PK parameters, clinical
      activity, durability of response and safety of GSK2118436 and GSK1120212 dosed orally in
      combination and GSK2118436 as monotherapy were evaluated.

      Part D consisted of evaluation of the pharmacokinetics of GSK2118436 HPMC capsules
      administered as monotherapy and in combination with GSK1120212. Pharmacokinetics of
      GSK2118436 was assessed following a single dose on Day 1 and after repeat dosing (Day 21) and
      compared between combination and monotherapy. The pharmacokinetics of GSK1120212 was also be
      assessed. Safety, tolerability and clinical activity were evaluated in 4 dosing cohorts.
      These cohorts might be expanded for additional safety data. Subjects were randomized to
      different cohorts.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 26, 2010</start_date>
  <completion_date type="Actual">February 27, 2018</completion_date>
  <primary_completion_date type="Actual">May 31, 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Part A: Maximum Plasma Concentration (Cmax) of a Single Dose of Dabrafenib Administered Alone and in Combination With Trametnib</measure>
    <time_frame>Day 15</time_frame>
    <description>Blood samples for PK analysis of dabrafenib and its the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at pre-dose and at 1, 2, 3, 4, 6, 8, 10, and 24 hours after dabrafenib administration. From the plasma concentration-time curve, the PK parameter Cmax was determined by standard non-compartmental analysis using WinNonlin. Cmax data are reported as geometric least squares means.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part A: AUC (0-t) and AUC (0-inf) of Dabrafenib and Its Metabolites</measure>
    <time_frame>Day 15</time_frame>
    <description>Blood samples for PK analysis of dabrafenib and its metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at pre-dose and at 1, 2, 3, 4, 6, 8, 10, and 24 hours after dabrafenib administration. AUC is defined as the area under the dabrafenib concentration-time curve as a measure of drug exposure. AUC (0-inf) is defined as the area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time. AUC (0-t) is defined as area under the concentration-time curve from time zero (pre-dose) to the last time of quantifiable concentration. Date are reported as geometric least square means.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 8 years)</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 8 years)</time_frame>
    <description>Clinical Chemistry parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 8 years)</time_frame>
    <description>For Clinical Chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 8 years)</time_frame>
    <description>Hematology parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 8 years)</time_frame>
    <description>For Hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part B: Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 8 years)</time_frame>
    <description>Blood pressure and heart rate were summarized according to NCI CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred. Blood pressure measurement included systolic blood pressure (SBP, millimeters of mercury [mmHg]) and diastolic BP (DBP). Heart rate is the measure of heart beats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C (Randomized): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator</measure>
    <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 7 years)</time_frame>
    <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeters [mm] in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C (Randomized): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response Assessed by Blinded Independent Central Review (BICR)</measure>
    <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 19 months)</time_frame>
    <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by BICR as per RECIST, version 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C (Crossover): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator</measure>
    <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 7 years)</time_frame>
    <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per RECIST, version 1.1.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C (Randomized): Progression-free Survival (PFS) as Assessed by the Investigator</measure>
    <time_frame>From the date of randomization to the earliest date of disease progression (PD) or death due to any cause (up to approximately 7 years)</time_frame>
    <description>PFS is defined as the interval between the date of randomization and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not had a documented date of events, PFS and survival were censored at the date of the last adequate assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C (Crossover): Progression-free Survival (PFS) as Assessed by the Investigator</measure>
    <time_frame>From the first dose of study medication to the earliest date of disease progression (PD) or death due to any cause (up to approximately 7 years)</time_frame>
    <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants received anti-cancer therapy prior to the date of documented events, and censored at the last adequate assessment, prior to the initiation of therapy. If the participant did not have a documented date of events, PFS and survival were censored at the date of the last adequate assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C (Randomized): Progression-free Survival (PFS) as Assessed by the Blinded Independent Central Review (BICR)</measure>
    <time_frame>From the date of randomization to the earliest date of disease progression (PD) or death due to any cause (up to approximately 19 months)</time_frame>
    <description>PFS is defined as the interval between the date of randomization and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the BICR according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not had a documented date of events, PFS and survival were censored at the date of the last adequate assessment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C (Randomized): Duration of Response as Assessed by the Investigator and Blinded Independent Central Review (BICR)</measure>
    <time_frame>First documented evidence of PR or CR until the date of the first documented sign of disease progression or the date of death due to any cause (up to approximately 19 months)</time_frame>
    <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C (Randomized): Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C (Randomized): Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
    <description>Clinical Chemistry parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C (Randomized): Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
    <description>For Clinical Chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C (Randomized): Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
    <description>Hematology parameters were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C (Randomized): Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
    <description>For Hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part C (Randomized): Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
    <description>Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, milimeter of mercury [mmHg]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heart beats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part D (Analyte=GSK2118436): Maximum Plasma Concentration (Cmax) of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>The PK parameter Cmax was assessed. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (24 hour on Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin. Cmax data are reported as geometric least squares means.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part D (Analyte=GSK2118436): Tmax of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>tmax is defined as the time of occurenceof Cmax. Blood samples for PK analysis of dabrafenib were obtained at Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours (24 hour on Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part D (Analyte=GSK2118436): AUC (0-tau) and AUC (0-inf) of Single and Repeat Doses of Dabrafenib Alone and in Combination With Trametinib</measure>
    <time_frame>Day 1 and Day 21</time_frame>
    <description>The PK parameters were determined for area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration AUC (0-tau) and from time zero (pre-dose) extrapolated to infinite time AUC (0-inf). Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (24 hour only on Day 1) post-dose administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part D: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
    <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event for possible drug-induced liver injury.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part D: Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
    <description>Clinical Chemistry parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part D: Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
    <description>For Clinical Chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part D: Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
    <description>Hematology parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part D: Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
    <description>For Hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Part D: Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure</measure>
    <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
    <description>Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, milimeter of mercury [mmHg]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heartbeats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Part A: Steady State Concentration of Trametinib With Concomitant Administration of Dabrafenib</measure>
    <time_frame>Day 15 and Day 16</time_frame>
    <description>The steady state plasma concentration (Css) of trametinib with concomitant dabrafenib administration was assessed at Day 15 and Day 16. At steady state the amount of drug administered (in a given time period) is equal to the amount of drug eliminated.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: AUC [0-tau] of Dabrafenib (DAB) and Its Metabolite in Combination With Trametinib</measure>
    <time_frame>Day 15 and Day 21</time_frame>
    <description>Area under the concentration-time curve from time zero (predose) until the last time of quantifiable concentration (AUC [0-tau]) was assessed. Blood samples for PK analysis of dabrafenib and its the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) and Maximum Plasma Concentration (Cmax) of Dabrafenib and Its Metabolite in Combination With Trametinib</measure>
    <time_frame>Day 15 and Day 21</time_frame>
    <description>Pre-dose (trough) concentration at the end of the dosing interval (Ctau) and maximum plasma concentration (Cmax) were assessed for plasma dabrafenib (DAB) following repeat dosing of DAB administered in combination with trametinib (T). The trough concentration is defined as the plasma level of a pharmaceutical product measured just before the next dose. Blood samples for PK analysis of the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Tmax of Dabrafenib and Its Metabolite in Combination With Trametinib</measure>
    <time_frame>Day 15 and Day 21</time_frame>
    <description>The tmax is defined as the time of occurenceof Cmax. Tha tmax was assessed for plasma dabrafenib (DAB) following repeat dosing of dabrafenib 75 and 150 mg BID administered in combination with trametinib. Blood samples for PK analysis of the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Analyte=GSK1120212): AUC (0-tau) Assessment of Trametinib in Combination With Dabrafenib</measure>
    <time_frame>Day 15 and Day 21</time_frame>
    <description>AUC (0-tau) is defined as area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration. AUC (0-tau) was assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Analyte=GSK1120212): Ctau and Cmax Assessments of Trametinib in Combination With Dabrafenib</measure>
    <time_frame>Day 15 and Day 21</time_frame>
    <description>Pre-dose (trough) concentration at the end of the dosing interval (Ctau) and maximum plasma concentration (Cmax) were assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose or Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B (Analyte=GSK1120212): Tmax Assessment of Trametinib in Combination With Dabrafenib</measure>
    <time_frame>Day 15 and Day 21</time_frame>
    <description>The tmax is defined as the time of occurrence of Cmax. The PK parameter for tmax was assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose or Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Number of Participants With BRAFi-naïve Mutant Metastatic Melanoma With the Best Overall Response as Assessed by Investigator</measure>
    <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 8 years)</time_frame>
    <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 milimeter [mm] in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing response were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. BRAFi-naïve participants were those with BRAF-mutation-positive melanoma who had not received prior therapy with a BRAF inhibitor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Duration of Response as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma</measure>
    <time_frame>First documented evidence of PR or CR until the earlier of date of disease progression or date of death due to any cause (up to approximately 8 years)</time_frame>
    <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. BRAFi-naïve participants were those with BRAF-mutation-positive melanoma who had not received prior therapy with a BRAF inhibitor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Progression-free Survival (PFS) as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma</measure>
    <time_frame>From the date of first dose to the earliest date of disease progression (PD) or death due to any cause (up to approximately 8 years)</time_frame>
    <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. BRAFi-naïve were the participants with BRAF-mutation positive melanoma who had not received prior therapy with a BRAF-inhibitor..</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Overall Survival (OS) in BRAFi Naïve Melanoma Participants</measure>
    <time_frame>From the date of first dose until date of death due to any cause (up to approximately 8 years)</time_frame>
    <description>OS is defined as the interval of time between the first dose of study medication until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part B: Pre- and Post-dose H-scores for Individual Participants</measure>
    <time_frame>Screening and at disease progression (up to approximately 8 years)</time_frame>
    <description>p-ERK and p-AKT, biomarkers in tumor biopsies, were assessed for participants with BRAF mutant colorectal cancer. The H-score, which is a composite score that comprises intensity and percentage of staining, is a method of assessing the amount of protein or phospho-protein present in a biopsy sample. The score is obtained by the formula: (3 * percentage of strongly staining nuclei) + (2 * percentage of moderately staining nuclei) + (percentage of weakly staining nuclei). The H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C (Randomized): Overall Survival (OS)</measure>
    <time_frame>From the date of randomization until date of death due to any cause (up to approximately 7 years)</time_frame>
    <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact. When calculating overall survival, deaths following crossover were included.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Plasma Concentrations of Dabrafenib and Its Metabolites</measure>
    <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, and Week 56</time_frame>
    <description>Plasma concentrations of dabrafenib and its metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were assesed following daily dose of dabrafenib and trametinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Plasma Concentrations of Trametinib</measure>
    <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, and Week 56</time_frame>
    <description>Plasma concentrations of trametinib was assessed following daily dose of dabrafenib and trametinib.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Oral Clearance (CL/F) of Dabrafenib and Trametinib</measure>
    <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48</time_frame>
    <description>Oral clearance (CL/F) of dabrafenib and trametinib were assessed using a population approach. Oral clearance (CL/F) is defined as the apparent volume of plasma in the vascular compartment cleared of drug per unit time by the processes of metabolism and excretion. For dabrafenib, population CL/F is defined as inducible and non-inducible CL/F. As dabrafenib induces its own metabolism, total oral clearance at steady state includes a non-induced (Day 1) component and an induced component, as estimated by a population PK model.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part C: Oral Volume of Distribution (V/F) of Dabrafenib and Trametinib</measure>
    <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48</time_frame>
    <description>Oral volume of distribution (V/F) of dabrafenib and trametinib were assessed using a population approach. Oral volume of distribution (V/F) is defined as the apparent volume of distribution in the central compartment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Cmax of Dabrafenib Metabolites</measure>
    <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>The maximum concentration (Cmax) of dabrafenib metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Tmax of Dabrafenib Metabolites</measure>
    <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>The time to Cmax (tmax) of DAB metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measuered at Day 1 and Day 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Area Under the Concentration-time Curve (AUC) of Dabrafenib Metabolites</measure>
    <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>Area under the concentration-time curve (AUC) from pre-dose to dosing interval (AUC[0-tau]), from pre-dose to the last time of quantifable concentration (AUC[0-tau]), and from pre-dose extrapolated to infinity (AUC[0-inf]) of DAB metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Cmax Assessment of Trametinib</measure>
    <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>Cmax of trametinib after single and repeat dose in combination with DAB was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, Cmax was not analyzed in these participants at Days 1 and 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Tmax Assessment of Trametinib</measure>
    <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>The tmax of trametinib after single and repeat dose in combination with dabrafenib (DAB) was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, tmax was not analyzed in these participants at Days 1 and 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Area Under the Concentration-time Curve Assessment of Trametinib</measure>
    <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
    <description>AUC(0-tau) after single and repeat dose of teametinib alone and in combination with dabrafenib was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, AUC(0-tau) was not analyzed in these participants at Days 1 and 21.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Number of Participants With the Best Overall Response as Assessed by the Investigator in Participants</measure>
    <time_frame>From the date of first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 7 years)</time_frame>
    <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 milimeter [mm] in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). To be assigned a status of PR or CR, a confirmatory disease assessment should be performed no less than 28 days after the criteria for response are first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Duration of Response as Assessed by the Investigator</measure>
    <time_frame>First documented evidence of PR or CR until the earlier of date of disease progression or date of death due to any cause (up to approximately 7 years)</time_frame>
    <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Progression-free Survival (PFS) as Assessed by the Investigator</measure>
    <time_frame>From the date of randomization to the earliest date of disease progression (PD) or death due to any cause (up to approximately 7 years)</time_frame>
    <description>PFS is defined as the interval between the date of randomization and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Part D: Overall Survival (OS)</measure>
    <time_frame>From the date of first dose until date of death due to any cause (up to approximately 7 years)</time_frame>
    <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">430</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Arm Part A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Day 1: GSK2118436 75mg; Day 2 through Day 16: GSK1120212 2mg; Day 15: GSK2118436 75mg +GSK1120212 2mg Drug-drug interaction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Part B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2118436 + GSK1120212 Dose escalation to a maximum tolerated combination dose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm Part C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK2118436 + GSK1120212 cohort expansion for safety and efficacy</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK2118436</intervention_name>
    <description>GSK2118436 is a potent and selective inhibitor of BRAF kinase activity with a mode of action consistent with adenosine triphosphate-competitive inhibition.</description>
    <arm_group_label>Arm Part A</arm_group_label>
    <arm_group_label>Arm Part B</arm_group_label>
    <arm_group_label>Arm Part C</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1120212</intervention_name>
    <description>GSK1120212 is a potent and highly selective inhibitor of MEK1/2 activation and kinase activity.</description>
    <arm_group_label>Arm Part A</arm_group_label>
    <arm_group_label>Arm Part C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:

          -  Capable of given written informed consent, which includes compliance with the
             requirements and restrictions listed in the consent form.

          -  Male or female age 18 years or greater; able to swallow and retain oral medication.

          -  BRAF mutation positive melanoma or colorectal cancer; other BRAF mutation positive
             tumor types may be considered.

          -  Measurable disease according to RECIST version 1.1.

          -  Eastern Cooperative Oncology Group Performance Status of 0 or 1 for Parts A and B.
             Subjects with Eastern Cooperative Oncology Group Performance Status of 2 or less may
             be entered into Part C with approval of medical monitor.

          -  Agree to contraception requirements.

          -  Calcium phosphorus product less than 4.0mmol2/L2.

          -  Adequate organ system function.

        Key Exclusion Criteria:

          -  Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or
             biologic therapy).

          -  Part A and Part B: Prior exposure to BRAF or MEK inhibitors unless approved by the GSK
             Medical Monitor.

          -  Part C: Prior exposure to BRAF or MEK inhibitors. Prior anti-cancer therapy in the
             metastatic setting, with the exception of up to one regimen of chemotherapy and/or
             interleukin-2 (IL-2).

          -  Part D: Prior exposure to BRAF inhibitors. A washout period of 6 weeks is required for
             ipilimumab.

          -  Received an investigational anti-cancer drug within 4 weeks or 5 half-lives (whichever
             is shorter) of study drug administration--- at least 14 days must have passed between
             the last dose of prior investigational anti-cancer drug and the first dose of study
             drug.

          -  Current use of a prohibited medication or requires any of these medications during
             treatment with study drug.

          -  Current use of therapeutic warfarin.

          -  Any major surgery, radiotherapy, or immunotherapy within the last 4 weeks. Limited
             radiotherapy within the last 2 weeks.

          -  Chemotherapy regimens with delayed toxicity within the last 4 weeks. Chemotherapy
             regimens given continuously or on a weekly basis with limited potential for delayed
             toxicity within the last 2 weeks.

          -  Unresolved toxicity greater than National Cancer Institute-Common Terminology Criteria
             for Adverse Events version 4 Grade 1 from previous anti-cancer therapy except
             alopecia.

          -  History of retinal vein occlusion, central serous retinopathy or glaucoma.

          -  Predisposing factors to retinal vein occlusion including uncontrolled hypertension,
             uncontrolled diabetes, uncontrolled hyperlipidemia, and coagulopathy.

          -  Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk
             factor for retinal vein occlusion or central serous retinopathy.

          -  Intraocular pressure greater than 21mm Hg as measured by tonography.

          -  Glaucoma diagnosed within one month prior to study Day 1.

          -  Presence of active gastrointestinal disease or other condition that will interfere
             significantly with the absorption, distribution, metabolism or excretion of drugs.

          -  Known human immunodeficiency virus, Hepatitis B or Hepatitis C infection.

          -  Primary malignancy of the central nervous system.

          -  Untreated or symptomatic brain metastasis, leptomeningeal disease or spinal cord
             compression. Subjects who are on a stable dose of corticosteroids for more than 1
             month or off corticosteroids for 2 weeks can be enrolled with approval of medical
             monitor. Subjects are not permitted to receive enzyme-inducing anti-epileptic drugs.

          -  Subjects with brain metastases are excluded, unless

             a. All known lesions must be previously treated with surgery or stereotactic
             radiosurgery, and- b. Brain lesion(s), if still present, must be confirmed stable
             (i.e. no increase in lesion size) for ≥90 days prior to first dose on study (must be
             documented with two consecutive MRI or CT scans using contrast), and c. Asymptomatic
             with no corticosteroids requirement for ≥ 30 days prior to first dose on study, and d.
             No enzyme-inducing anticonvulsants for ≥ 30 days prior to first dose on study.

          -  History of alcohol or drug abuse within 6 months prior to screening.

          -  Psychological, familial, sociological or geographical conditions that do not permit
             compliance with the protocol.

          -  QTc interval greater than or equal to 480msecs.

          -  History of acute coronary syndromes (including unstable angina), coronary angioplasty,
             or stenting within the past 24 weeks.

          -  Class II, III, or IV heart failure as defined by the New York Heart Association
             functional classification system.

          -  Abnormal cardiac valve morphology (subjects with minimal abnormalities can be entered
             on study with approval from the medical monitor.

          -  Treatment refractory hypertension defined as a blood pressure of systolic&gt; 140 mmHg
             and/or diastolic &gt; 90 mm Hg which cannot be controlled by anti-hypertensive therapy

          -  Patients with intra-cardiac defibrillators or permanent pacemakers.

          -  Cardiac metastases

          -  Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs
             chemically related to the study drugs or excipients.

          -  Pregnant or lactating female.

          -  Unwillingness or inability to follow the procedures required in the protocol.

          -  Uncontrolled diabetes, hypertension or other medical conditions that may interfere
             with assessment of toxicity.

          -  Subjects with known glucose 6 phosphate dehydrogenase deficiency.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06520</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lutherville-Timonium</city>
        <state>Maryland</state>
        <zip>21093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, Hamid O, Schuchter L, Cebon J, Ibrahim N, Kudchadkar R, Burris HA 3rd, Falchook G, Algazi A, Lewis K, Long GV, Puzanov I, Lebowitz P, Singh A, Little S, Sun P, Allred A, Ouellet D, Kim KB, Patel K, Weber J. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med. 2012 Nov 1;367(18):1694-703. doi: 10.1056/NEJMoa1210093. Epub 2012 Sep 29.</citation>
    <PMID>23020132</PMID>
  </reference>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>February 12, 2010</study_first_submitted>
  <study_first_submitted_qc>February 18, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2010</study_first_posted>
  <results_first_submitted>June 27, 2013</results_first_submitted>
  <results_first_submitted_qc>September 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 21, 2013</results_first_posted>
  <last_update_submitted>June 25, 2019</last_update_submitted>
  <last_update_submitted_qc>June 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug-drug interaction</keyword>
  <keyword>BRAF inhibitor</keyword>
  <keyword>expansion cohorts</keyword>
  <keyword>melanoma</keyword>
  <keyword>dose escalation</keyword>
  <keyword>MEK inhibitor</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trametinib</mesh_term>
    <mesh_term>Dabrafenib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was conducted in 16 sites: Australia (2) and USA (14)</recruitment_details>
      <pre_assignment_details>The study was comprised of Parts A, B, and D, which constitute the Phase I part of the study, and Part C, which constitutes the randomized Phase II part of the study. Participants did not enroll in all parts of the study sequentially. Each part of the study was comprised of a separate population of participants.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Part A: Dabrafenib 75 mg + Trametinib 2 mg</title>
          <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).</description>
        </group>
        <group group_id="P2">
          <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="P3">
          <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="P4">
          <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="P5">
          <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
        </group>
        <group group_id="P6">
          <title>Part C (Randomized): Dabrafenib 150 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
        </group>
        <group group_id="P7">
          <title>Part C (Randomized): Dabrafenib 150 mg + Trametinib 1 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
        </group>
        <group group_id="P8">
          <title>Part C (Randomized): Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="P9">
          <title>Part C (Crossover): Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants who received dabrafenib 150 mg capsules BID alone in the Randomized Phase were given the opportunity to receive combination dosing of dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD upon disease progression with approval of the GlaxoSmithKline (GSK) Medical Monitor.</description>
        </group>
        <group group_id="P10">
          <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
        </group>
        <group group_id="P11">
          <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
        </group>
        <group group_id="P12">
          <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="P13">
          <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Part A (Drug-Drug Interaction)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part B (Dose Escalation and Expansion)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="94"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="23"/>
                <participants group_id="P4" count="27"/>
                <participants group_id="P5" count="94"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="18"/>
                <participants group_id="P4" count="21"/>
                <participants group_id="P5" count="68"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="4"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study closed/terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="10"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part C (Phase II: Randomized Phase)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="54"/>
                <participants group_id="P8" count="54"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="54"/>
                <participants group_id="P7" count="54"/>
                <participants group_id="P8" count="54"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="44"/>
                <participants group_id="P7" count="34"/>
                <participants group_id="P8" count="39"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
                <participants group_id="P7" count="1"/>
                <participants group_id="P8" count="1"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="3"/>
                <participants group_id="P8" count="3"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study closed/terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="6"/>
                <participants group_id="P7" count="9"/>
                <participants group_id="P8" count="11"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="7"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part C (Phase II: Crossover Phase [CP])</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="45"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="45"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="37"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="1"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study closed/terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="4"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="3"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Part D (HPMC Capsules)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="43"/>
                <participants group_id="P13" count="39"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="0"/>
                <participants group_id="P12" count="0"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="12"/>
                <participants group_id="P11" count="16"/>
                <participants group_id="P12" count="43"/>
                <participants group_id="P13" count="39"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="10"/>
                <participants group_id="P11" count="12"/>
                <participants group_id="P12" count="28"/>
                <participants group_id="P13" count="26"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="1"/>
                <participants group_id="P13" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study closed/terminated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="2"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="10"/>
                <participants group_id="P13" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
                <participants group_id="P8" count="0"/>
                <participants group_id="P9" count="0"/>
                <participants group_id="P10" count="0"/>
                <participants group_id="P11" count="1"/>
                <participants group_id="P12" count="3"/>
                <participants group_id="P13" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Part A: Dabrafenib 75 mg + Trametinib 2 mg</title>
          <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).</description>
        </group>
        <group group_id="B2">
          <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="B3">
          <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="B4">
          <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="B5">
          <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
        </group>
        <group group_id="B6">
          <title>Part C: Dabrafenib 150 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
        </group>
        <group group_id="B7">
          <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
        </group>
        <group group_id="B8">
          <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="B9">
          <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
        </group>
        <group group_id="B10">
          <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
        </group>
        <group group_id="B11">
          <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="B12">
          <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="B13">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="23"/>
            <count group_id="B4" value="27"/>
            <count group_id="B5" value="94"/>
            <count group_id="B6" value="54"/>
            <count group_id="B7" value="54"/>
            <count group_id="B8" value="54"/>
            <count group_id="B9" value="12"/>
            <count group_id="B10" value="16"/>
            <count group_id="B11" value="43"/>
            <count group_id="B12" value="39"/>
            <count group_id="B13" value="430"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.8" spread="16.04"/>
                    <measurement group_id="B2" value="48.2" spread="7.28"/>
                    <measurement group_id="B3" value="54.2" spread="13.24"/>
                    <measurement group_id="B4" value="52.2" spread="12.09"/>
                    <measurement group_id="B5" value="52.4" spread="12.99"/>
                    <measurement group_id="B6" value="51.8" spread="15.19"/>
                    <measurement group_id="B7" value="49.9" spread="14.70"/>
                    <measurement group_id="B8" value="55.9" spread="11.85"/>
                    <measurement group_id="B9" value="51.8" spread="12.39"/>
                    <measurement group_id="B10" value="53.1" spread="17.04"/>
                    <measurement group_id="B11" value="52.8" spread="14.57"/>
                    <measurement group_id="B12" value="56.7" spread="14.08"/>
                    <measurement group_id="B13" value="52.8" spread="13.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="56"/>
                    <measurement group_id="B6" value="25"/>
                    <measurement group_id="B7" value="24"/>
                    <measurement group_id="B8" value="20"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="18"/>
                    <measurement group_id="B12" value="14"/>
                    <measurement group_id="B13" value="197"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="13"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="38"/>
                    <measurement group_id="B6" value="29"/>
                    <measurement group_id="B7" value="30"/>
                    <measurement group_id="B8" value="34"/>
                    <measurement group_id="B9" value="6"/>
                    <measurement group_id="B10" value="8"/>
                    <measurement group_id="B11" value="25"/>
                    <measurement group_id="B12" value="25"/>
                    <measurement group_id="B13" value="233"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="26"/>
                    <measurement group_id="B5" value="92"/>
                    <measurement group_id="B6" value="52"/>
                    <measurement group_id="B7" value="54"/>
                    <measurement group_id="B8" value="53"/>
                    <measurement group_id="B9" value="12"/>
                    <measurement group_id="B10" value="16"/>
                    <measurement group_id="B11" value="43"/>
                    <measurement group_id="B12" value="39"/>
                    <measurement group_id="B13" value="407"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="1"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="0"/>
                    <measurement group_id="B9" value="0"/>
                    <measurement group_id="B10" value="0"/>
                    <measurement group_id="B11" value="0"/>
                    <measurement group_id="B12" value="0"/>
                    <measurement group_id="B13" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Part A: Maximum Plasma Concentration (Cmax) of a Single Dose of Dabrafenib Administered Alone and in Combination With Trametnib</title>
        <description>Blood samples for PK analysis of dabrafenib and its the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at pre-dose and at 1, 2, 3, 4, 6, 8, 10, and 24 hours after dabrafenib administration. From the plasma concentration-time curve, the PK parameter Cmax was determined by standard non-compartmental analysis using WinNonlin. Cmax data are reported as geometric least squares means.</description>
        <time_frame>Day 15</time_frame>
        <population>Pharmacokinetic (PK) Population: all participants who received at least one dose of either dabrafenib or trametinib and for whom a PK sample was obtained and analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Dabrafenib 75 mg</title>
            <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules alone on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Maximum Plasma Concentration (Cmax) of a Single Dose of Dabrafenib Administered Alone and in Combination With Trametnib</title>
          <description>Blood samples for PK analysis of dabrafenib and its the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at pre-dose and at 1, 2, 3, 4, 6, 8, 10, and 24 hours after dabrafenib administration. From the plasma concentration-time curve, the PK parameter Cmax was determined by standard non-compartmental analysis using WinNonlin. Cmax data are reported as geometric least squares means.</description>
          <population>Pharmacokinetic (PK) Population: all participants who received at least one dose of either dabrafenib or trametinib and for whom a PK sample was obtained and analyzed</population>
          <units>Nanograms per milliliter (ng/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2118436</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="509" lower_limit="379" upper_limit="685"/>
                    <measurement group_id="O2" value="524" lower_limit="390" upper_limit="705"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="259" lower_limit="190" upper_limit="352"/>
                    <measurement group_id="O2" value="255" lower_limit="196" upper_limit="331"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="724" lower_limit="595" upper_limit="879"/>
                    <measurement group_id="O2" value="747" lower_limit="587" upper_limit="951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.37" lower_limit="4.82" upper_limit="14.5"/>
                    <measurement group_id="O2" value="8.16" lower_limit="5.68" upper_limit="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cmax of dabrafenib was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.34</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 Cmax/Day 1 Cmax) and 90% confidence interval for dabrafenib were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cmax of GSK2285403 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>.99</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 Cmax/Day 1 Cmax) and 90% confidence interval for GSK2285403 were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cmax of GSK2298683 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.03</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.27</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 Cmax/Day 1 Cmax) and 90% confidence interval for GSK2298683 were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Cmax of GSK2167542 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>.98</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.66</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 Cmax/Day 1 Cmax) and 90% confidence interval for GSK2167542 were calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part A: AUC (0-t) and AUC (0-inf) of Dabrafenib and Its Metabolites</title>
        <description>Blood samples for PK analysis of dabrafenib and its metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at pre-dose and at 1, 2, 3, 4, 6, 8, 10, and 24 hours after dabrafenib administration. AUC is defined as the area under the dabrafenib concentration-time curve as a measure of drug exposure. AUC (0-inf) is defined as the area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time. AUC (0-t) is defined as area under the concentration-time curve from time zero (pre-dose) to the last time of quantifiable concentration. Date are reported as geometric least square means.</description>
        <time_frame>Day 15</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Dabrafenib 75 mg</title>
            <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules alone on Day 1.</description>
          </group>
          <group group_id="O2">
            <title>Part A: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: AUC (0-t) and AUC (0-inf) of Dabrafenib and Its Metabolites</title>
          <description>Blood samples for PK analysis of dabrafenib and its metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at pre-dose and at 1, 2, 3, 4, 6, 8, 10, and 24 hours after dabrafenib administration. AUC is defined as the area under the dabrafenib concentration-time curve as a measure of drug exposure. AUC (0-inf) is defined as the area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time. AUC (0-t) is defined as area under the concentration-time curve from time zero (pre-dose) to the last time of quantifiable concentration. Date are reported as geometric least square means.</description>
          <population>PK Population</population>
          <units>ng*hour/mL (ng*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2118436 AUC (0-t)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2734" lower_limit="2205" upper_limit="3390"/>
                    <measurement group_id="O2" value="2751" lower_limit="2219" upper_limit="3411"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2118436 AUC (0-inf)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3128" lower_limit="2578" upper_limit="3797"/>
                    <measurement group_id="O2" value="2949" lower_limit="2445" upper_limit="3556"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 AUC (0-t)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2232" lower_limit="1684" upper_limit="2959"/>
                    <measurement group_id="O2" value="2287" lower_limit="1899" upper_limit="2753"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 AUC (0-inf)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2819" lower_limit="2231" upper_limit="3562"/>
                    <measurement group_id="O2" value="2497" lower_limit="2097" upper_limit="2974"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 AUC (0-t)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12761" lower_limit="10347" upper_limit="15738"/>
                    <measurement group_id="O2" value="13053" lower_limit="10475" upper_limit="16266"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 AUC (0-inf)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
            <class>
              <title>GSK2167542 AUC (0-t)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="8"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="270" lower_limit="188" upper_limit="390"/>
                    <measurement group_id="O2" value="276" lower_limit="230" upper_limit="332"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 AUC (0-inf)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>AUC(0-t) of dabrafenib was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.01</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.19</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 AUC(0-inf)/ Day 1 AUC(0-inf)) and 90% confidence interval for dabrafenib were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>AUC(0-inf) of dabrafenib was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.94</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 AUC(0-inf)/ Day 1 AUC(0-inf)) and 90% confidence interval for dabrafenib were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>AUC(0-t) of GSK2285403 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.25</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 AUC(0-t)/ Day 1 AUC(0-t)) and 90% confidence interval for GSK2285403 were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>AUC(0-inf) of GSK2285403 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>0.92</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.03</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 AUC(0-inf)/ Day 1 AUC(0-inf)) and 90% confidence interval for GSK2285403 were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>AUC(0-t) of GSK2298683 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.81</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 AUC(0-t)/ Day 1 AUC(0-t)) and 90% confidence interval for GSK2298683 were calculated.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>AUC(0-t) of GSK2167542 was log e transformed and analyzed by a linear mixed effect model with fixed effect for treatment (dabrafenib alone and combined with trametinib) and participant as a random effect. Geometric mean ratio (Day 15/Day 1) and 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.02</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.76</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 15 AUC(0-t)/ Day 1 AUC(0-t)) and 90% confidence interval for GSK2167542 were calculated.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</title>
        <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 8 years)</time_frame>
        <population>All Treated Participants (ATP) Population: all participants who received at least one dose of either dabrafenib or trametinib</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</title>
          <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is defined as any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury.</description>
          <population>All Treated Participants (ATP) Population: all participants who received at least one dose of either dabrafenib or trametinib</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="27"/>
                    <measurement group_id="O4" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="14"/>
                    <measurement group_id="O4" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline</title>
        <description>Clinical Chemistry parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 8 years)</time_frame>
        <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline</title>
          <description>Clinical Chemistry parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
          <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (Hypercalcemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (Hypocalcemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (Hyperglycemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (Hypoglycemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (Hyperkalemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (Hypokalemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium (Hypermagnesemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium (Hypomagnesemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (Hypernatremia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (Hyponatremia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="7"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Blood pH</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus inorganic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range</title>
        <description>For Clinical Chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 8 years)</time_frame>
        <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range</title>
          <description>For Clinical Chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
          <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indirect Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase MB mass</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="55"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="39"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carbon dioxide content/Bicarbonate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="17"/>
                    <count group_id="O4" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine clearance</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate dehydrogenase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total protein</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="37"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Trponin T</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline</title>
        <description>Hematology parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 8 years)</time_frame>
        <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline</title>
          <description>Hematology parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
          <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin (Increased)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (Anemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Increased)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Decreased)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="8"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="10"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range</title>
        <description>For Hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 8 years)</time_frame>
        <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range</title>
          <description>For Hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
          <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="94"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="13"/>
                    <count group_id="O4" value="39"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin concentration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="16"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="14"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="19"/>
                    <count group_id="O4" value="51"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="9"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="27"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="11"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part B: Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure</title>
        <description>Blood pressure and heart rate were summarized according to NCI CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred. Blood pressure measurement included systolic blood pressure (SBP, millimeters of mercury [mmHg]) and diastolic BP (DBP). Heart rate is the measure of heart beats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 8 years)</time_frame>
        <population>ATP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure</title>
          <description>Blood pressure and heart rate were summarized according to NCI CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred. Blood pressure measurement included systolic blood pressure (SBP, millimeters of mercury [mmHg]) and diastolic BP (DBP). Heart rate is the measure of heart beats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented.</description>
          <population>ATP Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="23"/>
                <count group_id="O3" value="27"/>
                <count group_id="O4" value="78"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart rate, Decrease to &lt;60 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Change to normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Increase to &gt;100 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SBP, Increase to G3 or G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP, Increase to G3 or G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part C (Randomized): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator</title>
        <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeters [mm] in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.</description>
        <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 7 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants regardless of whether or not treatment was administered</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Randomized): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator</title>
          <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 millimeters [mm] in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants regardless of whether or not treatment was administered</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="21"/>
                    <measurement group_id="O3" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in response rate Arm2 - Arm1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Unconditional exact method</param_type>
            <param_value>-4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-23.1</ci_lower_limit>
            <ci_upper_limit>15.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in response rate Arm3 - Arm1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Unconditional exact method</param_type>
            <param_value>22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.5</ci_lower_limit>
            <ci_upper_limit>40.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part C (Randomized): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response Assessed by Blinded Independent Central Review (BICR)</title>
        <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by BICR as per RECIST, version 1.1.</description>
        <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 19 months)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Randomized): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response Assessed by Blinded Independent Central Review (BICR)</title>
          <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by BICR as per RECIST, version 1.1.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="18"/>
                    <measurement group_id="O3" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Difference in response rate Arm2- Arm1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Unconditional exact method</param_type>
            <param_value>-6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-24.9</ci_lower_limit>
            <ci_upper_limit>14.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Difference in response rate Arm3 - Arm1</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Unconditional exact method</param_type>
            <param_value>15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-4.9</ci_lower_limit>
            <ci_upper_limit>33.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part C (Crossover): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator</title>
        <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per RECIST, version 1.1.</description>
        <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 7 years)</time_frame>
        <population>Crossover Population: participants who were randomized to and received at least one dose of dabrafenib monotherapy, and who elected to crossover to combination therapy following disease progression while on monotherapy</population>
        <group_list>
          <group group_id="O1">
            <title>Part C (Crossover): Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants who received dabrafenib 150 mg capsules BID alone in the Randomized Phase were given the opportunity to receive combination dosing of dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD upon disease progression with approval of the GlaxoSmithKline (GSK) Medical Monitor.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Crossover): Number of Participants With BRAF Mutant Metastatic Melanoma With Best Overall Response as Assessed by the Investigator</title>
          <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing responses were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per RECIST, version 1.1.</description>
          <population>Crossover Population: participants who were randomized to and received at least one dose of dabrafenib monotherapy, and who elected to crossover to combination therapy following disease progression while on monotherapy</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Response rate</param_type>
            <param_value>6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>5.1</ci_lower_limit>
            <ci_upper_limit>26.8</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part C (Randomized): Progression-free Survival (PFS) as Assessed by the Investigator</title>
        <description>PFS is defined as the interval between the date of randomization and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not had a documented date of events, PFS and survival were censored at the date of the last adequate assessment.</description>
        <time_frame>From the date of randomization to the earliest date of disease progression (PD) or death due to any cause (up to approximately 7 years)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Randomized): Progression-free Survival (PFS) as Assessed by the Investigator</title>
          <description>PFS is defined as the interval between the date of randomization and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not had a documented date of events, PFS and survival were censored at the date of the last adequate assessment.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" lower_limit="4.3" upper_limit="7.4"/>
                    <measurement group_id="O2" value="9.2" lower_limit="5.7" upper_limit="11.0"/>
                    <measurement group_id="O3" value="9.4" lower_limit="7.6" upper_limit="16.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0048</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.58</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.38</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
            <estimate_desc>HRs were estimated using the Pike estimator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>0.68</ci_upper_limit>
            <estimate_desc>HRs were estimated using the Pike estimator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part C (Crossover): Progression-free Survival (PFS) as Assessed by the Investigator</title>
        <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants received anti-cancer therapy prior to the date of documented events, and censored at the last adequate assessment, prior to the initiation of therapy. If the participant did not have a documented date of events, PFS and survival were censored at the date of the last adequate assessment.</description>
        <time_frame>From the first dose of study medication to the earliest date of disease progression (PD) or death due to any cause (up to approximately 7 years)</time_frame>
        <population>Crossover Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C (Crossover): Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants who received dabrafenib 150 mg capsules BID alone in the Randomized Phase were given the opportunity to receive combination dosing of dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD upon disease progression with approval of the GlaxoSmithKline (GSK) Medical Monitor.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Crossover): Progression-free Survival (PFS) as Assessed by the Investigator</title>
          <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants received anti-cancer therapy prior to the date of documented events, and censored at the last adequate assessment, prior to the initiation of therapy. If the participant did not have a documented date of events, PFS and survival were censored at the date of the last adequate assessment.</description>
          <population>Crossover Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="45"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" lower_limit="1.8" upper_limit="3.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part C (Randomized): Progression-free Survival (PFS) as Assessed by the Blinded Independent Central Review (BICR)</title>
        <description>PFS is defined as the interval between the date of randomization and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the BICR according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not had a documented date of events, PFS and survival were censored at the date of the last adequate assessment</description>
        <time_frame>From the date of randomization to the earliest date of disease progression (PD) or death due to any cause (up to approximately 19 months)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Randomized): Progression-free Survival (PFS) as Assessed by the Blinded Independent Central Review (BICR)</title>
          <description>PFS is defined as the interval between the date of randomization and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the BICR according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. Participants who received anti-cancer therapy prior to the date of documented events, were censored at the last adequate assessment prior to the initiation of therapy. If the participant did not had a documented date of events, PFS and survival were censored at the date of the last adequate assessment</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.3" lower_limit="5.5" upper_limit="9.4"/>
                    <measurement group_id="O2" value="8.3" lower_limit="5.6" upper_limit="11.3"/>
                    <measurement group_id="O3" value="9.2" lower_limit="7.6" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.1667</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.73</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.45</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
            <estimate_desc>HRs were estimated using the Pike estimator.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0119</p_value>
            <method>Log Rank</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.54</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.32</ci_lower_limit>
            <ci_upper_limit>0.90</ci_upper_limit>
            <estimate_desc>HRs were estimated using the Pike estimator.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part C (Randomized): Duration of Response as Assessed by the Investigator and Blinded Independent Central Review (BICR)</title>
        <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
        <time_frame>First documented evidence of PR or CR until the date of the first documented sign of disease progression or the date of death due to any cause (up to approximately 19 months)</time_frame>
        <population>ITT Population. Only those participants who had a CR or PR were analyzed for duration of response.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Randomized): Duration of Response as Assessed by the Investigator and Blinded Independent Central Review (BICR)</title>
          <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
          <population>ITT Population. Only those participants who had a CR or PR were analyzed for duration of response.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Investigator assessed</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="29"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="41"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="3.9" upper_limit="7.4"/>
                    <measurement group_id="O2" value="11.1" lower_limit="7.4" upper_limit="13.2"/>
                    <measurement group_id="O3" value="10.5" lower_limit="7.4" upper_limit="19.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>BICR assessed</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="25"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="33"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.6" lower_limit="4.7" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="9.5" lower_limit="5.6" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="NA" lower_limit="6.7" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part C (Randomized): Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</title>
        <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
        <population>ATP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Randomized): Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</title>
          <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event of possible drug-induced liver injury.</description>
          <population>ATP Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="53"/>
                    <measurement group_id="O3" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part C (Randomized): Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline</title>
        <description>Clinical Chemistry parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
        <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Randomized): Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline</title>
          <description>Clinical Chemistry parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
          <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (Hypercalcemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (Hypocalcemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (Hyperglycemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (Hypoglycemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (Hyperkalemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (Hypokalemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium (Hypermagnesemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium (Hypomagnesemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (Hypernatremia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (Hyponatremia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus inorganic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part C (Randomized): Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range</title>
        <description>For Clinical Chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
        <population>ATP Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Randomized): Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range</title>
          <description>For Clinical Chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
          <population>ATP Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase MB mass</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="18"/>
                    <count group_id="O2" value="38"/>
                    <count group_id="O3" value="36"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="24"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carbon dioxide content/Bicarbonate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="28"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-Reactive protein</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Clearance</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="14"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Density Lipids, Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate Dehydrogenase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Density Lipids, Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="18"/>
                    <count group_id="O3" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="27"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part C (Randomized): Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline</title>
        <description>Hematology parameters were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
        <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Randomized): Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline</title>
          <description>Hematology parameters were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3, Severe; Grade 4, Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
          <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin (Increased)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (Anemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Increased)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Decreased)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet Count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part C (Randomized): Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range</title>
        <description>For Hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
        <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Randomized): Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range</title>
          <description>For Hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
          <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="22"/>
                    <count group_id="O3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="17"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="23"/>
                    <measurement group_id="O3" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin concentration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="13"/>
                    <count group_id="O2" value="24"/>
                    <count group_id="O3" value="21"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="10"/>
                    <count group_id="O2" value="17"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="22"/>
                    <count group_id="O2" value="34"/>
                    <count group_id="O3" value="26"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="20"/>
                    <measurement group_id="O3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="12"/>
                    <count group_id="O2" value="26"/>
                    <count group_id="O3" value="29"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="22"/>
                    <measurement group_id="O3" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="7"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part C (Randomized): Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure</title>
        <description>Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, milimeter of mercury [mmHg]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heart beats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
        <population>ATP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Randomized): Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure</title>
          <description>Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, milimeter of mercury [mmHg]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heart beats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented.</description>
          <population>ATP Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="55"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Systolic BP (mmHg) , G3 or G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP (mmHg), G3 or G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Decrease to &lt;60 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Change to normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="30"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Increase to &gt;100 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part D (Analyte=GSK2118436): Maximum Plasma Concentration (Cmax) of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib</title>
        <description>The PK parameter Cmax was assessed. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (24 hour on Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin. Cmax data are reported as geometric least squares means.</description>
        <time_frame>Day 1 and Day 21</time_frame>
        <population>PK Population: all participants who received at least one dose of either dabrafenib or trametinib and for whom a PK sample was obtained and analyzed</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D (Analyte=GSK2118436): Maximum Plasma Concentration (Cmax) of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib</title>
          <description>The PK parameter Cmax was assessed. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (24 hour on Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin. Cmax data are reported as geometric least squares means.</description>
          <population>PK Population: all participants who received at least one dose of either dabrafenib or trametinib and for whom a PK sample was obtained and analyzed</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1117" lower_limit="914" upper_limit="1365"/>
                    <measurement group_id="O2" value="1669" lower_limit="1059" upper_limit="2631"/>
                    <measurement group_id="O3" value="1227" lower_limit="924" upper_limit="1764"/>
                    <measurement group_id="O4" value="2289" lower_limit="1622" upper_limit="3231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1050" lower_limit="811" upper_limit="1358"/>
                    <measurement group_id="O2" value="1746" lower_limit="1344" upper_limit="2269"/>
                    <measurement group_id="O3" value="1217" lower_limit="895" upper_limit="1654"/>
                    <measurement group_id="O4" value="2052" lower_limit="1472" upper_limit="2860"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Following loge tranformation, Cmax of dabrafenib after repeat doses from the pooled data in Part B and D were analyzed by a linear model with the following fixed effects as categorical variables: Capsule type (Gelatin or HPMC), BRAF dose (75 or 150 mg BID), Capsule type by BRAF dose interaction, Day (Day 15 or 21), MEK dose (0, 1, 1.5 or 2 mg QD). Geometric mean ratio (HPMC/Gelatin) and the corresponding 90% CI were provided for BRAF dose level 150 mg BID.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.51</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.10</ci_lower_limit>
            <ci_upper_limit>2.08</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (HPMC/Gelatin) and the corresponding 90% CI were provided for BRAF dose level 150 mg BID.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part D (Analyte=GSK2118436): Tmax of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib</title>
        <description>tmax is defined as the time of occurenceof Cmax. Blood samples for PK analysis of dabrafenib were obtained at Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours (24 hour on Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.</description>
        <time_frame>Day 1 and Day 21</time_frame>
        <population>PK Population. Only participants available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D (Analyte=GSK2118436): Tmax of a Single and Repeat Dose of Dabrafenib Alone and in Combination With Trametinib</title>
          <description>tmax is defined as the time of occurenceof Cmax. Blood samples for PK analysis of dabrafenib were obtained at Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours (24 hour on Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.</description>
          <population>PK Population. Only participants available at the indicated timepoints were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.00" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.50" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O2" value="1.55" lower_limit="0.98" upper_limit="3.00"/>
                    <measurement group_id="O3" value="1.75" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.00" upper_limit="3.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part D (Analyte=GSK2118436): AUC (0-tau) and AUC (0-inf) of Single and Repeat Doses of Dabrafenib Alone and in Combination With Trametinib</title>
        <description>The PK parameters were determined for area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration AUC (0-tau) and from time zero (pre-dose) extrapolated to infinite time AUC (0-inf). Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (24 hour only on Day 1) post-dose administration.</description>
        <time_frame>Day 1 and Day 21</time_frame>
        <population>PK Population. Only participants available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D (Analyte=GSK2118436): AUC (0-tau) and AUC (0-inf) of Single and Repeat Doses of Dabrafenib Alone and in Combination With Trametinib</title>
          <description>The PK parameters were determined for area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration AUC (0-tau) and from time zero (pre-dose) extrapolated to infinite time AUC (0-inf). Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (24 hour only on Day 1) post-dose administration.</description>
          <population>PK Population. Only participants available at the indicated timepoints were analyzed.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AUC (0-tau), Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3593" lower_limit="3008" upper_limit="4293"/>
                    <measurement group_id="O2" value="6507" lower_limit="4288" upper_limit="9872"/>
                    <measurement group_id="O3" value="4618" lower_limit="3525" upper_limit="6051"/>
                    <measurement group_id="O4" value="7331" lower_limit="5355" upper_limit="10037"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-tau), Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3020" lower_limit="2390" upper_limit="3816"/>
                    <measurement group_id="O2" value="4663" lower_limit="3511" upper_limit="6194"/>
                    <measurement group_id="O3" value="3434" lower_limit="2679" upper_limit="4403"/>
                    <measurement group_id="O4" value="5886" lower_limit="4608" upper_limit="7517"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-inf), Day 1</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="15"/>
                    <count group_id="O2" value="14"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="15"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3982" lower_limit="3325" upper_limit="4770"/>
                    <measurement group_id="O2" value="7291" lower_limit="4830" upper_limit="11005"/>
                    <measurement group_id="O3" value="5321" lower_limit="4192" upper_limit="6755"/>
                    <measurement group_id="O4" value="8152" lower_limit="5860" upper_limit="11341"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AUC (0-inf), Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Following loge transformation, AUC(0-tau) of dabrafenib was analyzed by a linear mixed effect model with dosing chort and day as fixed effects and subject as random effect. Based on the model, geometric mean ratio (Day 21 Dabrafenib 150 mg BID+Trametinib 2 mg QD/Day 21 Dabrafenib 150 mg BID alone) and the corresponding 90% confidence interval were provided.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.23</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.89</ci_lower_limit>
            <ci_upper_limit>1.69</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (Day 21 Dabrafenib 150 mg BID+Trametinib 2 mg QD/Day 21 Dabrafenib 150 mg BID alone) and the corresponding 90% confidence interval were provided.</estimate_desc>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Following loge tranformation, AUC(0-tau) of dabrafenib after repeat doses from the pooled data in Part B and D were analyzed by a linear model with the following fixed effects as categorical variables: Capsule type (Gelatin or HPMC), BRAF dose (75 or 150 mg BID), Capsule type by BRAF dose interaction, Day (Day 15 or 21), MEK dose (0, 1, 1.5, 2 or 2 mg QD). Geometric mean ratio (HPMC/Gelatin) and the corresponding 90% CI were then provided for BRAF dose level 150 mg BID.</non_inferiority_desc>
            <param_type>Geometric Mean Ratio</param_type>
            <param_value>1.10</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.84</ci_lower_limit>
            <ci_upper_limit>1.44</ci_upper_limit>
            <estimate_desc>Geometric mean ratio (HPMC/Gelatin) and the corresponding 90% CI were provided for BRAF dose level 150 mg BID.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part D: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</title>
        <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event for possible drug-induced liver injury.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
        <population>ATP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Number of Participants With Any Adverse Event (AE) or Serious Adverse Event (SAE)</title>
          <description>An AE is defined as any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product. An SAE is any untoward medical occurrence that, at any dose, results in death, is life threatening, requires hospitalization or prolongation of existing hospitalization, results in disability/incapacity, is a congenital anomaly/birth defect, or is an event for possible drug-induced liver injury.</description>
          <population>ATP Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any AE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="15"/>
                    <measurement group_id="O3" value="41"/>
                    <measurement group_id="O4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any SAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="29"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part D: Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline</title>
        <description>Clinical Chemistry parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
        <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Number of Participants With Worst-case Chemistry Toxicity Grade Change From Baseline</title>
          <description>Clinical Chemistry parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
          <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Albumin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alkaline Phosphatase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Alanine Amino Transferase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Amylase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aspartate Amino Transferase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (Hypercalcemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Calcium (Hypocalcemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gamma Glutamyl Transferase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="3"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (Hyperglycemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="4"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Glucose (Hypoglycemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (Hyperkalemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Potassium (Hypokalemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium (Hypermagnesemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Magnesium (Hypomagnesemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (Hypernatremia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sodium (Hyponatremia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="6"/>
                    <count group_id="O4" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus inorganic</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uric acid</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part D: Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range</title>
        <description>For Clinical Chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
        <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Number of Participants With Worst-case Chemistry Change From Baseline With Respect to Normal Range</title>
          <description>For Clinical Chemistry parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
          <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Direct Bilirubin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatine Kinase MB mass</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chloride</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="11"/>
                    <count group_id="O3" value="25"/>
                    <count group_id="O4" value="34"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="25"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Carbon dioxide content/Bicarbonate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="24"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>C-Reactive protein</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine Clearance</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="6"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High Density Lipids cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lactate Dehydrogenase</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="24"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="20"/>
                    <measurement group_id="O4" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Low Density Lipids cholesterol</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Protein</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="23"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin I</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Troponin T</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urea/BUN</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part D: Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline</title>
        <description>Hematology parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
        <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Number of Participants With Worst-case Hematology Toxicity Grade Change From Baseline</title>
          <description>Hematology parameters were summarized according to National Cancer Institutes (NCI) Common Terminology Criteria for Adverse Events (CTCAE) grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to Grade 3 or Grade 4 occurred. Participants with missing Baseline Grade were assumed to have Baseline Grade of 0. All increases were an increase in grade from Baseline. Only descriptive analysis.</description>
          <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Hemoglobin (Increased)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin (Anemia)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Increased)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphocytes (Decreased)</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total Neutrophils</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="1"/>
                    <count group_id="O3" value="3"/>
                    <count group_id="O4" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="1"/>
                    <count group_id="O4" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="2"/>
                    <count group_id="O4" value="3"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Increase to Grade 3</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to Grade 4</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part D: Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range</title>
        <description>For Hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
        <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Number of Participants With Worst-case Hematology Change From Baseline With Respect to Normal Range</title>
          <description>For Hematology parameters that were not graded according to NCI CTCAE criteria, changes above (High) and below (Low) the normal range were evaluated. Participants with missing Baseline were assumed to be within normal range. Participants were counted twice if the subject &quot;Decreased to Low&quot; and Increase to High&quot; during the post-baseline period. Only descriptive analysis.</description>
          <population>All Treated Participants (ATP) Population. Only participants with lab values at the specified planned time were considered.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="41"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Basophils</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1"/>
                    <count group_id="O2" value="2"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eosinophils</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="9"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="6"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Erythrocyte Sedimentation Rate</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="0"/>
                    <count group_id="O4" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hematocrit</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="21"/>
                    <count group_id="O4" value="20"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="19"/>
                    <measurement group_id="O4" value="18"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin concentration</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="9"/>
                    <count group_id="O2" value="7"/>
                    <count group_id="O3" value="18"/>
                    <count group_id="O4" value="12"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Hemoglobin</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2"/>
                    <count group_id="O2" value="5"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mean Corpuscle Volume</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                    <count group_id="O3" value="10"/>
                    <count group_id="O4" value="11"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Monocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="11"/>
                    <count group_id="O2" value="10"/>
                    <count group_id="O3" value="29"/>
                    <count group_id="O4" value="25"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="17"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Red Blood Cell count</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="31"/>
                    <count group_id="O4" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Reticulocytes</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="0"/>
                    <count group_id="O3" value="5"/>
                    <count group_id="O4" value="2"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Decrease to Low</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Increase to High</title>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Part D: Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure</title>
        <description>Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, milimeter of mercury [mmHg]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heartbeats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented</description>
        <time_frame>From Baseline (Day 1) until Follow-up visit (up to approximately 7 years)</time_frame>
        <population>ATP Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Number of Participants With the Indicated Worst-case Change From Baseline in Heart Rate and Blood Pressure</title>
          <description>Blood pressure were summarized according to National Cancer Institutes (NCI) CTCAE grade, version 4.0. Grade 1, Mild; Grade 2, Moderate; Grade 3 (G3), Severe; Grade 4 (G4), Life-threatening or disabling; Grade 5, Death. Data are presented for only those parameters for which an increase to G3 or G4 occurred.lood pressure measurement included systolic blood pressure (BP, milimeter of mercury [mmHg]) and diastolic BP (DBP). Worst case change from Baseline was calculated as the post-Baseline value minus the Baseline value. Heart Rate is the measure of heartbeats per minute (bpm). Changes in heart rate, either decrease to &lt;60 bpm, change to normal or no change, or increase to &gt;100 bpm are presented</description>
          <population>ATP Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="15"/>
                <count group_id="O3" value="40"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Heart rate, Decrease to &lt;60 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Change to normal or no change</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                    <measurement group_id="O3" value="18"/>
                    <measurement group_id="O4" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Heart rate, Increase to &gt;100 bpm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systolic BP (mmHg) , increase to G3 or G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diastolic BP (mmHg), increase to G3 or G4</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part A: Steady State Concentration of Trametinib With Concomitant Administration of Dabrafenib</title>
        <description>The steady state plasma concentration (Css) of trametinib with concomitant dabrafenib administration was assessed at Day 15 and Day 16. At steady state the amount of drug administered (in a given time period) is equal to the amount of drug eliminated.</description>
        <time_frame>Day 15 and Day 16</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part A: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).</description>
          </group>
        </group_list>
        <measure>
          <title>Part A: Steady State Concentration of Trametinib With Concomitant Administration of Dabrafenib</title>
          <description>The steady state plasma concentration (Css) of trametinib with concomitant dabrafenib administration was assessed at Day 15 and Day 16. At steady state the amount of drug administered (in a given time period) is equal to the amount of drug eliminated.</description>
          <population>PK Population</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.7" lower_limit="6" upper_limit="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="6" upper_limit="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: AUC [0-tau] of Dabrafenib (DAB) and Its Metabolite in Combination With Trametinib</title>
        <description>Area under the concentration-time curve from time zero (predose) until the last time of quantifiable concentration (AUC [0-tau]) was assessed. Blood samples for PK analysis of dabrafenib and its the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
        <time_frame>Day 15 and Day 21</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: AUC [0-tau] of Dabrafenib (DAB) and Its Metabolite in Combination With Trametinib</title>
          <description>Area under the concentration-time curve from time zero (predose) until the last time of quantifiable concentration (AUC [0-tau]) was assessed. Blood samples for PK analysis of dabrafenib and its the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
          <population>PK Population. Only those participants who were available at the indicated time point were analyzed.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAB, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2466" lower_limit="1458" upper_limit="4171"/>
                    <measurement group_id="O2" value="3539" lower_limit="1634" upper_limit="7666"/>
                    <measurement group_id="O3" value="5187" lower_limit="3737" upper_limit="7199"/>
                    <measurement group_id="O4" value="4114" lower_limit="1560" upper_limit="10848"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAB, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4656" lower_limit="3901" upper_limit="5557"/>
                    <measurement group_id="O3" value="4528" lower_limit="3602" upper_limit="5692"/>
                    <measurement group_id="O4" value="5518" lower_limit="3732" upper_limit="8158"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2120" lower_limit="1366" upper_limit="3290"/>
                    <measurement group_id="O2" value="2163" lower_limit="1267" upper_limit="3694"/>
                    <measurement group_id="O3" value="3136" lower_limit="2501" upper_limit="3932"/>
                    <measurement group_id="O4" value="3180" lower_limit="1389" upper_limit="7283"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3257" lower_limit="2162" upper_limit="4907"/>
                    <measurement group_id="O3" value="2989" lower_limit="2545" upper_limit="3510"/>
                    <measurement group_id="O4" value="3632" lower_limit="2364" upper_limit="5581"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="37159" lower_limit="22389" upper_limit="61673"/>
                    <measurement group_id="O2" value="40634" lower_limit="30329" upper_limit="54441"/>
                    <measurement group_id="O3" value="43727" lower_limit="31486" upper_limit="60727"/>
                    <measurement group_id="O4" value="68528" lower_limit="42444" upper_limit="110642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 , Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="47911" lower_limit="30643" upper_limit="74909"/>
                    <measurement group_id="O3" value="49939" lower_limit="39219" upper_limit="63589"/>
                    <measurement group_id="O4" value="59965" lower_limit="45117" upper_limit="79699"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2859" lower_limit="1568" upper_limit="5216"/>
                    <measurement group_id="O2" value="2961" lower_limit="1206" upper_limit="7270"/>
                    <measurement group_id="O3" value="4156" lower_limit="2802" upper_limit="6165"/>
                    <measurement group_id="O4" value="3746" lower_limit="1992" upper_limit="7043"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="3609" lower_limit="2279" upper_limit="5714"/>
                    <measurement group_id="O3" value="2995" lower_limit="1891" upper_limit="4743"/>
                    <measurement group_id="O4" value="3961" lower_limit="2361" upper_limit="6645"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) and Maximum Plasma Concentration (Cmax) of Dabrafenib and Its Metabolite in Combination With Trametinib</title>
        <description>Pre-dose (trough) concentration at the end of the dosing interval (Ctau) and maximum plasma concentration (Cmax) were assessed for plasma dabrafenib (DAB) following repeat dosing of DAB administered in combination with trametinib (T). The trough concentration is defined as the plasma level of a pharmaceutical product measured just before the next dose. Blood samples for PK analysis of the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
        <time_frame>Day 15 and Day 21</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Pre-dose (Trough) Concentration at the End of the Dosing Interval (Ctau) and Maximum Plasma Concentration (Cmax) of Dabrafenib and Its Metabolite in Combination With Trametinib</title>
          <description>Pre-dose (trough) concentration at the end of the dosing interval (Ctau) and maximum plasma concentration (Cmax) were assessed for plasma dabrafenib (DAB) following repeat dosing of DAB administered in combination with trametinib (T). The trough concentration is defined as the plasma level of a pharmaceutical product measured just before the next dose. Blood samples for PK analysis of the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
          <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAB Ctau, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.8" lower_limit="19.1" upper_limit="187"/>
                    <measurement group_id="O2" value="44.6" lower_limit="17.1" upper_limit="117"/>
                    <measurement group_id="O3" value="115" lower_limit="27.8" upper_limit="472"/>
                    <measurement group_id="O4" value="73.7" lower_limit="10.3" upper_limit="528"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAB Ctau, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="185" lower_limit="79.7" upper_limit="428"/>
                    <measurement group_id="O3" value="102" lower_limit="57.1" upper_limit="184"/>
                    <measurement group_id="O4" value="79.9" lower_limit="32.2" upper_limit="198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAB Cmax, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="640" lower_limit="390" upper_limit="1048"/>
                    <measurement group_id="O2" value="906" lower_limit="221" upper_limit="3717"/>
                    <measurement group_id="O3" value="1306" lower_limit="700" upper_limit="2437"/>
                    <measurement group_id="O4" value="1046" lower_limit="545" upper_limit="2011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAB Cmax, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1263" lower_limit="863" upper_limit="1848"/>
                    <measurement group_id="O3" value="1346" lower_limit="997" upper_limit="1817"/>
                    <measurement group_id="O4" value="1391" lower_limit="1002" upper_limit="1932"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 Ctau, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.9" lower_limit="25.2" upper_limit="211"/>
                    <measurement group_id="O2" value="47.8" lower_limit="20.2" upper_limit="113"/>
                    <measurement group_id="O3" value="97.9" lower_limit="32.2" upper_limit="297"/>
                    <measurement group_id="O4" value="74.4" lower_limit="15.7" upper_limit="353"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 Ctau, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="136" lower_limit="62.4" upper_limit="299"/>
                    <measurement group_id="O3" value="92.9" lower_limit="60.2" upper_limit="143"/>
                    <measurement group_id="O4" value="82.7" lower_limit="37.6" upper_limit="182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 Cmax, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="399" lower_limit="265" upper_limit="601"/>
                    <measurement group_id="O2" value="418" lower_limit="146" upper_limit="1201"/>
                    <measurement group_id="O3" value="597" lower_limit="300" upper_limit="1186"/>
                    <measurement group_id="O4" value="630" lower_limit="411" upper_limit="964"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 Cmax, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="775" lower_limit="441" upper_limit="1364"/>
                    <measurement group_id="O3" value="668" lower_limit="507" upper_limit="882"/>
                    <measurement group_id="O4" value="722" lower_limit="502" upper_limit="1039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 Ctau, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2345" lower_limit="1237" upper_limit="4447"/>
                    <measurement group_id="O2" value="2360" lower_limit="1134" upper_limit="4911"/>
                    <measurement group_id="O3" value="2792" lower_limit="2069" upper_limit="3768"/>
                    <measurement group_id="O4" value="4372" lower_limit="2589" upper_limit="7384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 Ctau, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2920" lower_limit="1674" upper_limit="5095"/>
                    <measurement group_id="O3" value="3221" lower_limit="2619" upper_limit="3962"/>
                    <measurement group_id="O4" value="3740" lower_limit="2564" upper_limit="5455"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 Cmax, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3757" lower_limit="2385" upper_limit="5916"/>
                    <measurement group_id="O2" value="4545" lower_limit="3817" upper_limit="5411"/>
                    <measurement group_id="O3" value="4636" lower_limit="3258" upper_limit="6598"/>
                    <measurement group_id="O4" value="7098" lower_limit="4914" upper_limit="10254"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 Cmax, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5301" lower_limit="3392" upper_limit="8286"/>
                    <measurement group_id="O3" value="5416" lower_limit="4163" upper_limit="7048"/>
                    <measurement group_id="O4" value="6257" lower_limit="4937" upper_limit="7931"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 Ctau, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257" lower_limit="140" upper_limit="473"/>
                    <measurement group_id="O2" value="249" lower_limit="79.4" upper_limit="782"/>
                    <measurement group_id="O3" value="331" lower_limit="185" upper_limit="590"/>
                    <measurement group_id="O4" value="318" lower_limit="260" upper_limit="389"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 Ctau, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="196" lower_limit="90.8" upper_limit="425"/>
                    <measurement group_id="O3" value="248" lower_limit="140" upper_limit="439"/>
                    <measurement group_id="O4" value="369" lower_limit="191" upper_limit="714"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 Cmax, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300" lower_limit="157" upper_limit="572"/>
                    <measurement group_id="O2" value="355" lower_limit="114" upper_limit="1108"/>
                    <measurement group_id="O3" value="523" lower_limit="251" upper_limit="1091"/>
                    <measurement group_id="O4" value="460" lower_limit="190" upper_limit="1113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 Cmax, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="543" lower_limit="298" upper_limit="989"/>
                    <measurement group_id="O3" value="373" lower_limit="248" upper_limit="562"/>
                    <measurement group_id="O4" value="430" lower_limit="226" upper_limit="818"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Tmax of Dabrafenib and Its Metabolite in Combination With Trametinib</title>
        <description>The tmax is defined as the time of occurenceof Cmax. Tha tmax was assessed for plasma dabrafenib (DAB) following repeat dosing of dabrafenib 75 and 150 mg BID administered in combination with trametinib. Blood samples for PK analysis of the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
        <time_frame>Day 15 and Day 21</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Tmax of Dabrafenib and Its Metabolite in Combination With Trametinib</title>
          <description>The tmax is defined as the time of occurenceof Cmax. Tha tmax was assessed for plasma dabrafenib (DAB) following repeat dosing of dabrafenib 75 and 150 mg BID administered in combination with trametinib. Blood samples for PK analysis of the metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
          <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>DAB Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.03" upper_limit="2.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.03" upper_limit="6.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="2.10"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DAB Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.54" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="1.53" lower_limit="1.00" upper_limit="2.03"/>
                    <measurement group_id="O4" value="2.04" lower_limit="1.00" upper_limit="4.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="2.00" upper_limit="2.03"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.03" upper_limit="8.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="2.00" upper_limit="4.03"/>
                    <measurement group_id="O4" value="2.00" lower_limit="2.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403 Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="1.97" lower_limit="0.00" upper_limit="2.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="2.03"/>
                    <measurement group_id="O4" value="2.07" lower_limit="1.00" upper_limit="6.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.00" lower_limit="4.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="4.96" lower_limit="0.00" upper_limit="6.30"/>
                    <measurement group_id="O3" value="4.17" lower_limit="1.00" upper_limit="8.02"/>
                    <measurement group_id="O4" value="4.10" lower_limit="4.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683 Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="4.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="4.00" lower_limit="1.00" upper_limit="6.00"/>
                    <measurement group_id="O4" value="4.02" lower_limit="2.00" upper_limit="8.07"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.00" lower_limit="0.00" upper_limit="4.17"/>
                    <measurement group_id="O2" value="2.94" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="4.17" lower_limit="1.00" upper_limit="8.02"/>
                    <measurement group_id="O4" value="1.52" lower_limit="0.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542 Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="2.32"/>
                    <measurement group_id="O3" value="1.01" lower_limit="0.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="0.00" upper_limit="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B (Analyte=GSK1120212): AUC (0-tau) Assessment of Trametinib in Combination With Dabrafenib</title>
        <description>AUC (0-tau) is defined as area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration. AUC (0-tau) was assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
        <time_frame>Day 15 and Day 21</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B (Analyte=GSK1120212): AUC (0-tau) Assessment of Trametinib in Combination With Dabrafenib</title>
          <description>AUC (0-tau) is defined as area under the concentration-time curve from time zero (pre-dose) to last time of quantifiable concentration. AUC (0-tau) was assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose and Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
          <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="169" lower_limit="113" upper_limit="252"/>
                    <measurement group_id="O2" value="147" lower_limit="101" upper_limit="212"/>
                    <measurement group_id="O3" value="217" lower_limit="139" upper_limit="338"/>
                    <measurement group_id="O4" value="394" lower_limit="229" upper_limit="679"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="169" lower_limit="146" upper_limit="194"/>
                    <measurement group_id="O3" value="269" lower_limit="238" upper_limit="304"/>
                    <measurement group_id="O4" value="351" lower_limit="284" upper_limit="432"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B (Analyte=GSK1120212): Ctau and Cmax Assessments of Trametinib in Combination With Dabrafenib</title>
        <description>Pre-dose (trough) concentration at the end of the dosing interval (Ctau) and maximum plasma concentration (Cmax) were assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose or Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
        <time_frame>Day 15 and Day 21</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B (Analyte=GSK1120212): Ctau and Cmax Assessments of Trametinib in Combination With Dabrafenib</title>
          <description>Pre-dose (trough) concentration at the end of the dosing interval (Ctau) and maximum plasma concentration (Cmax) were assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose or Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
          <population>PK Population. Only those participants who were available at the indicated time point were analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Ctau, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.56" lower_limit="3.74" upper_limit="8.28"/>
                    <measurement group_id="O2" value="5.05" lower_limit="3.81" upper_limit="6.69"/>
                    <measurement group_id="O3" value="7.62" lower_limit="5.38" upper_limit="10.8"/>
                    <measurement group_id="O4" value="12.4" lower_limit="6.50" upper_limit="23.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctau, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="5.57" lower_limit="4.80" upper_limit="6.45"/>
                    <measurement group_id="O3" value="8.51" lower_limit="7.65" upper_limit="9.48"/>
                    <measurement group_id="O4" value="10.8" lower_limit="8.75" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.2" lower_limit="7.18" upper_limit="14.4"/>
                    <measurement group_id="O2" value="8.08" lower_limit="5.06" upper_limit="12.9"/>
                    <measurement group_id="O3" value="11.5" lower_limit="6.16" upper_limit="21.5"/>
                    <measurement group_id="O4" value="22.4" lower_limit="14.0" upper_limit="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cmax, Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="10.2" lower_limit="8.50" upper_limit="12.1"/>
                    <measurement group_id="O3" value="18.0" lower_limit="14.9" upper_limit="21.7"/>
                    <measurement group_id="O4" value="22.6" lower_limit="18.1" upper_limit="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B (Analyte=GSK1120212): Tmax Assessment of Trametinib in Combination With Dabrafenib</title>
        <description>The tmax is defined as the time of occurrence of Cmax. The PK parameter for tmax was assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose or Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
        <time_frame>Day 15 and Day 21</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time point were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B (Analyte=GSK1120212): Tmax Assessment of Trametinib in Combination With Dabrafenib</title>
          <description>The tmax is defined as the time of occurrence of Cmax. The PK parameter for tmax was assessed for plasma trametinib following repeat dosing of trametinib in combination with dabrafenib. Blood samples for PK analysis of the metabolites of dabrafenib were obtained at Day 15 pre-dose or Day 21 pre-dose and at 1, 2, 4, 6, and 8 hours post-dose administration.</description>
          <population>PK Population. Only those participants who were available at the indicated time point were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="12"/>
                <count group_id="O4" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.03" upper_limit="4.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="8.00"/>
                    <measurement group_id="O4" value="1.52" lower_limit="1.00" upper_limit="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="0"/>
                    <count group_id="O2" value="8"/>
                    <count group_id="O3" value="12"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O2" value="2.00" lower_limit="0.93" upper_limit="8.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="2.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.00" upper_limit="8.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Number of Participants With BRAFi-naïve Mutant Metastatic Melanoma With the Best Overall Response as Assessed by Investigator</title>
        <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 milimeter [mm] in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing response were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. BRAFi-naïve participants were those with BRAF-mutation-positive melanoma who had not received prior therapy with a BRAF inhibitor.</description>
        <time_frame>From the first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 8 years)</time_frame>
        <population>All Treated Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Number of Participants With BRAFi-naïve Mutant Metastatic Melanoma With the Best Overall Response as Assessed by Investigator</title>
          <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 milimeter [mm] in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). Participants with unknown or missing response were considered as non-responders. To be assigned a status of PR or CR, a confirmatory disease assessment should have been performed no less than 28 days after the criteria for response were first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1. BRAFi-naïve participants were those with BRAF-mutation-positive melanoma who had not received prior therapy with a BRAF inhibitor.</description>
          <population>All Treated Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                    <measurement group_id="O3" value="3"/>
                    <measurement group_id="O4" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Duration of Response as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma</title>
        <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. BRAFi-naïve participants were those with BRAF-mutation-positive melanoma who had not received prior therapy with a BRAF inhibitor.</description>
        <time_frame>First documented evidence of PR or CR until the earlier of date of disease progression or date of death due to any cause (up to approximately 8 years)</time_frame>
        <population>All Treated Population. Only those participants who had a CR or PR were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Duration of Response as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma</title>
          <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. BRAFi-naïve participants were those with BRAF-mutation-positive melanoma who had not received prior therapy with a BRAF inhibitor.</description>
          <population>All Treated Population. Only those participants who had a CR or PR were analyzed.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.4" lower_limit="3.7" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="8.4" lower_limit="3.9" upper_limit="27.4"/>
                    <measurement group_id="O3" value="12.6" lower_limit="5.1" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O4" value="16.9" lower_limit="7.4" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Progression-free Survival (PFS) as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma</title>
        <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. BRAFi-naïve were the participants with BRAF-mutation positive melanoma who had not received prior therapy with a BRAF-inhibitor..</description>
        <time_frame>From the date of first dose to the earliest date of disease progression (PD) or death due to any cause (up to approximately 8 years)</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Progression-free Survival (PFS) as Assessed by the Investigator in Participants With BRAFi-naïve Mutant Metastatic Melanoma</title>
          <description>PFS is defined as the interval between the first dose of study medication and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm. BRAFi-naïve were the participants with BRAF-mutation positive melanoma who had not received prior therapy with a BRAF-inhibitor..</description>
          <population>All Treated Population.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.7" lower_limit="3.4" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="8.2" lower_limit="4.3" upper_limit="11.0"/>
                    <measurement group_id="O3" value="5.4" lower_limit="3.5" upper_limit="12.8"/>
                    <measurement group_id="O4" value="10.8" lower_limit="3.6" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Overall Survival (OS) in BRAFi Naïve Melanoma Participants</title>
        <description>OS is defined as the interval of time between the first dose of study medication until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact.</description>
        <time_frame>From the date of first dose until date of death due to any cause (up to approximately 8 years)</time_frame>
        <population>All Treated Population.</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O2">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O3">
            <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
          </group>
          <group group_id="O4">
            <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Overall Survival (OS) in BRAFi Naïve Melanoma Participants</title>
          <description>OS is defined as the interval of time between the first dose of study medication until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact.</description>
          <population>All Treated Population.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="22"/>
                <count group_id="O3" value="25"/>
                <count group_id="O4" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17.4" lower_limit="8.0" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O2" value="23.5" lower_limit="12.9" upper_limit="33.7"/>
                    <measurement group_id="O3" value="13.3" lower_limit="6.3" upper_limit="23.4"/>
                    <measurement group_id="O4" value="41.5" lower_limit="12.9" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part B: Pre- and Post-dose H-scores for Individual Participants</title>
        <description>p-ERK and p-AKT, biomarkers in tumor biopsies, were assessed for participants with BRAF mutant colorectal cancer. The H-score, which is a composite score that comprises intensity and percentage of staining, is a method of assessing the amount of protein or phospho-protein present in a biopsy sample. The score is obtained by the formula: (3 * percentage of strongly staining nuclei) + (2 * percentage of moderately staining nuclei) + (percentage of weakly staining nuclei). The H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.</description>
        <time_frame>Screening and at disease progression (up to approximately 8 years)</time_frame>
        <population>Biomarker Population: participants with H-score data for pre- and post-biopsy pairs</population>
        <group_list>
          <group group_id="O1">
            <title>Part B: Dabrafenib + Trametinib</title>
            <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib (75 mg or 150 mg) gelatin capsules BID and trametinib (1 mg, 1.5 mg, or 2 mg) tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
          </group>
        </group_list>
        <measure>
          <title>Part B: Pre- and Post-dose H-scores for Individual Participants</title>
          <description>p-ERK and p-AKT, biomarkers in tumor biopsies, were assessed for participants with BRAF mutant colorectal cancer. The H-score, which is a composite score that comprises intensity and percentage of staining, is a method of assessing the amount of protein or phospho-protein present in a biopsy sample. The score is obtained by the formula: (3 * percentage of strongly staining nuclei) + (2 * percentage of moderately staining nuclei) + (percentage of weakly staining nuclei). The H-score ranges from 0 to 300, with a score of 0 representing the absence of any of the target protein and an H-score of 300 representing maximum staining and intensity of the target protein.</description>
          <population>Biomarker Population: participants with H-score data for pre- and post-biopsy pairs</population>
          <units>scores on a scale</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>p-ERK: Participant 1, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 1, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 2, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 2, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="138"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 3, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 3, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 4, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 4, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 5, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 5, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 6, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 6, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 7, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 7, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 8, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 8, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 9, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 9, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="109"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 10, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-ERK: Participant 10, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 1, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 1, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 2, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 2, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 3, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 3, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 4, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 4, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="135"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 5, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 5, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 6, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 6, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 7, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 7, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 8, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="183"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 8, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="123"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 9, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="278"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 9, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="289"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT: Participant 10, pre-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>p-AKT, Participant 10, post-dose score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part C (Randomized): Overall Survival (OS)</title>
        <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact. When calculating overall survival, deaths following crossover were included.</description>
        <time_frame>From the date of randomization until date of death due to any cause (up to approximately 7 years)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C (Randomized): Overall Survival (OS)</title>
          <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact. When calculating overall survival, deaths following crossover were included.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
                <count group_id="O2" value="54"/>
                <count group_id="O3" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.2" lower_limit="14.0" upper_limit="27.1"/>
                    <measurement group_id="O2" value="18.7" lower_limit="13.7" upper_limit="35.3"/>
                    <measurement group_id="O3" value="25.0" lower_limit="17.5" upper_limit="36.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part C: Plasma Concentrations of Dabrafenib and Its Metabolites</title>
        <description>Plasma concentrations of dabrafenib and its metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were assesed following daily dose of dabrafenib and trametinib.</description>
        <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, and Week 56</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C: Plasma Concentrations of Dabrafenib and Its Metabolites</title>
          <description>Plasma concentrations of dabrafenib and its metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) were assesed following daily dose of dabrafenib and trametinib.</description>
          <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="49"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15, GSK2118436</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.3" lower_limit="9" upper_limit="2420"/>
                    <measurement group_id="O2" value="68.2" lower_limit="0" upper_limit="1555"/>
                    <measurement group_id="O3" value="66.3" lower_limit="7" upper_limit="1804"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, GSK2118436</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45.6" lower_limit="3" upper_limit="1841"/>
                    <measurement group_id="O2" value="69.8" lower_limit="0" upper_limit="946"/>
                    <measurement group_id="O3" value="50.5" lower_limit="0" upper_limit="1696"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, GSK2118436</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.4" lower_limit="0" upper_limit="1865"/>
                    <measurement group_id="O2" value="66.7" lower_limit="0" upper_limit="1774"/>
                    <measurement group_id="O3" value="82.9" lower_limit="2" upper_limit="3033"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, GSK2118436</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66.3" lower_limit="4" upper_limit="594"/>
                    <measurement group_id="O2" value="66.2" lower_limit="1" upper_limit="2684"/>
                    <measurement group_id="O3" value="93.3" lower_limit="7" upper_limit="741"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32, GSK2118436</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="40.6" lower_limit="1" upper_limit="500"/>
                    <measurement group_id="O2" value="57.1" lower_limit="0" upper_limit="1424"/>
                    <measurement group_id="O3" value="66.4" lower_limit="0" upper_limit="2042"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40, GSK2118436</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="229" lower_limit="5" upper_limit="714"/>
                    <measurement group_id="O2" value="97.6" lower_limit="19" upper_limit="2597"/>
                    <measurement group_id="O3" value="150.9" lower_limit="0" upper_limit="1624"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, GSK2118436</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7" lower_limit="13" upper_limit="132"/>
                    <measurement group_id="O2" value="105.6" lower_limit="0" upper_limit="1322"/>
                    <measurement group_id="O3" value="107.7" lower_limit="3" upper_limit="806"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56, GSK2118436</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.4" lower_limit="25" upper_limit="68"/>
                    <measurement group_id="O2" value="44.5" lower_limit="0" upper_limit="6646"/>
                    <measurement group_id="O3" value="193.8" lower_limit="3" upper_limit="413"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, GSK2285403</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="92.7" lower_limit="14" upper_limit="1337"/>
                    <measurement group_id="O2" value="71.8" lower_limit="2" upper_limit="1220"/>
                    <measurement group_id="O3" value="90.5" lower_limit="10" upper_limit="995"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, GSK2285403</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.2" lower_limit="3" upper_limit="2041"/>
                    <measurement group_id="O2" value="80.4" lower_limit="0" upper_limit="769"/>
                    <measurement group_id="O3" value="90.6" lower_limit="0" upper_limit="757"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, GSK2285403</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113.4" lower_limit="0" upper_limit="2090"/>
                    <measurement group_id="O2" value="81.9" lower_limit="0" upper_limit="995"/>
                    <measurement group_id="O3" value="114.7" lower_limit="3" upper_limit="2563"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, GSK2285403</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="95.0" lower_limit="4" upper_limit="616"/>
                    <measurement group_id="O2" value="88.1" lower_limit="0" upper_limit="1689"/>
                    <measurement group_id="O3" value="130.2" lower_limit="9" upper_limit="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32, GSK2285403</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.5" lower_limit="3" upper_limit="890"/>
                    <measurement group_id="O2" value="86.7" lower_limit="0" upper_limit="808"/>
                    <measurement group_id="O3" value="87.4" lower_limit="0" upper_limit="973"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40, GSK2285403</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="263.8" lower_limit="7" upper_limit="693"/>
                    <measurement group_id="O2" value="143.5" lower_limit="16" upper_limit="870"/>
                    <measurement group_id="O3" value="136.2" lower_limit="0" upper_limit="1665"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, GSK2285403</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43.3" lower_limit="32" upper_limit="241"/>
                    <measurement group_id="O2" value="93.6" lower_limit="0" upper_limit="898"/>
                    <measurement group_id="O3" value="146.4" lower_limit="2" upper_limit="418"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56, GSK2285403</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.3" lower_limit="45" upper_limit="51"/>
                    <measurement group_id="O2" value="92.9" lower_limit="0" upper_limit="1841"/>
                    <measurement group_id="O3" value="141.5" lower_limit="7" upper_limit="755"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, GSK2298683</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3493" lower_limit="1381" upper_limit="16820"/>
                    <measurement group_id="O2" value="3043.3" lower_limit="199" upper_limit="8562"/>
                    <measurement group_id="O3" value="3145.8" lower_limit="428" upper_limit="16240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, GSK2298683</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3149.7" lower_limit="238" upper_limit="13330"/>
                    <measurement group_id="O2" value="3238.4" lower_limit="20" upper_limit="7686"/>
                    <measurement group_id="O3" value="3010" lower_limit="31" upper_limit="13130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, GSK2298683</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3497.9" lower_limit="21" upper_limit="9952"/>
                    <measurement group_id="O2" value="2946.1" lower_limit="0" upper_limit="8782"/>
                    <measurement group_id="O3" value="2756.5" lower_limit="44" upper_limit="14004"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, GSK2298683</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2876.5" lower_limit="500" upper_limit="8635"/>
                    <measurement group_id="O2" value="3365.4" lower_limit="25" upper_limit="7482"/>
                    <measurement group_id="O3" value="3193.7" lower_limit="133" upper_limit="6531"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32, GSK2298683</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2699.9" lower_limit="447" upper_limit="14341"/>
                    <measurement group_id="O2" value="3267.1" lower_limit="0" upper_limit="9278"/>
                    <measurement group_id="O3" value="3046.8" lower_limit="50" upper_limit="9077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40, GSK2298683</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4410.6" lower_limit="1023" upper_limit="14258"/>
                    <measurement group_id="O2" value="3694.7" lower_limit="1900" upper_limit="7663"/>
                    <measurement group_id="O3" value="3492.8" lower_limit="0" upper_limit="12550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, GSK2298683</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3554.9" lower_limit="1889" upper_limit="7148"/>
                    <measurement group_id="O2" value="4146.9" lower_limit="0" upper_limit="8351"/>
                    <measurement group_id="O3" value="3936.1" lower_limit="464" upper_limit="12239"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56, GSK2298683</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2032.2" lower_limit="1102" upper_limit="2963"/>
                    <measurement group_id="O2" value="3843.5" lower_limit="374" upper_limit="6866"/>
                    <measurement group_id="O3" value="2904.9" lower_limit="1305" upper_limit="4673"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15, GSK2167542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.9" lower_limit="95" upper_limit="955"/>
                    <measurement group_id="O2" value="288" lower_limit="49" upper_limit="1164"/>
                    <measurement group_id="O3" value="289.3" lower_limit="72" upper_limit="1140"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, GSK2167542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="239.5" lower_limit="19" upper_limit="1092"/>
                    <measurement group_id="O2" value="275.2" lower_limit="3" upper_limit="983"/>
                    <measurement group_id="O3" value="262.4" lower_limit="0" upper_limit="9876"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, GSK2167542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="244" lower_limit="1" upper_limit="772"/>
                    <measurement group_id="O2" value="204.4" lower_limit="0" upper_limit="922"/>
                    <measurement group_id="O3" value="243.8" lower_limit="3" upper_limit="1049"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, GSK2167542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="225.6" lower_limit="48" upper_limit="899"/>
                    <measurement group_id="O2" value="247.2" lower_limit="4" upper_limit="990"/>
                    <measurement group_id="O3" value="254.6" lower_limit="3" upper_limit="846"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32, GSK2167542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171" lower_limit="19" upper_limit="544"/>
                    <measurement group_id="O2" value="255.4" lower_limit="0" upper_limit="698"/>
                    <measurement group_id="O3" value="289.3" lower_limit="2" upper_limit="962"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40, GSK2167542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="222.2" lower_limit="95" upper_limit="639"/>
                    <measurement group_id="O2" value="249.3" lower_limit="55" upper_limit="674"/>
                    <measurement group_id="O3" value="268.9" lower_limit="0" upper_limit="910"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, GSK2167542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204.5" lower_limit="145" upper_limit="286"/>
                    <measurement group_id="O2" value="232" lower_limit="0" upper_limit="915"/>
                    <measurement group_id="O3" value="260.9" lower_limit="81" upper_limit="886"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56, GSK2167542</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171.8" lower_limit="116" upper_limit="228"/>
                    <measurement group_id="O2" value="250" lower_limit="28" upper_limit="851"/>
                    <measurement group_id="O3" value="462.1" lower_limit="107" upper_limit="663"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part C: Plasma Concentrations of Trametinib</title>
        <description>Plasma concentrations of trametinib was assessed following daily dose of dabrafenib and trametinib.</description>
        <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, Week 48, and Week 56</time_frame>
        <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Dabrafenib 150 mg + Trametinib 1 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
          </group>
          <group group_id="O3">
            <title>Part C: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C: Plasma Concentrations of Trametinib</title>
          <description>Plasma concentrations of trametinib was assessed following daily dose of dabrafenib and trametinib.</description>
          <population>PK Population. Only those participants who were available at the indicated time points were analyzed.</population>
          <units>ng/mL</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="59"/>
                <count group_id="O2" value="53"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="5.86" lower_limit="3.4" upper_limit="11.3"/>
                    <measurement group_id="O3" value="9.35" lower_limit="4.8" upper_limit="26.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="13.9"/>
                    <measurement group_id="O2" value="6.70" lower_limit="2.0" upper_limit="9.6"/>
                    <measurement group_id="O3" value="10.3" lower_limit="0" upper_limit="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="9.8"/>
                    <measurement group_id="O2" value="6.99" lower_limit="0" upper_limit="20.7"/>
                    <measurement group_id="O3" value="9.87" lower_limit="1.1" upper_limit="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="19.7"/>
                    <measurement group_id="O2" value="5.99" lower_limit="0" upper_limit="11.2"/>
                    <measurement group_id="O3" value="9.54" lower_limit="0.5" upper_limit="27.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="5.77" lower_limit="0.7" upper_limit="11.6"/>
                    <measurement group_id="O3" value="9.74" lower_limit="0" upper_limit="51.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="7.11" lower_limit="2.2" upper_limit="16.7"/>
                    <measurement group_id="O3" value="10.1" lower_limit="0" upper_limit="26.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="5.62" lower_limit="0" upper_limit="14.3"/>
                    <measurement group_id="O3" value="10.3" lower_limit="0" upper_limit="35.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 56</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="0"/>
                    <measurement group_id="O2" value="9.90" lower_limit="3.4" upper_limit="16.9"/>
                    <measurement group_id="O3" value="8.60" lower_limit="0" upper_limit="15.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part C: Oral Clearance (CL/F) of Dabrafenib and Trametinib</title>
        <description>Oral clearance (CL/F) of dabrafenib and trametinib were assessed using a population approach. Oral clearance (CL/F) is defined as the apparent volume of plasma in the vascular compartment cleared of drug per unit time by the processes of metabolism and excretion. For dabrafenib, population CL/F is defined as inducible and non-inducible CL/F. As dabrafenib induces its own metabolism, total oral clearance at steady state includes a non-induced (Day 1) component and an induced component, as estimated by a population PK model.</description>
        <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Trametinib</title>
            <description>Participants received Trametinib 1 mg or 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C: Oral Clearance (CL/F) of Dabrafenib and Trametinib</title>
          <description>Oral clearance (CL/F) of dabrafenib and trametinib were assessed using a population approach. Oral clearance (CL/F) is defined as the apparent volume of plasma in the vascular compartment cleared of drug per unit time by the processes of metabolism and excretion. For dabrafenib, population CL/F is defined as inducible and non-inducible CL/F. As dabrafenib induces its own metabolism, total oral clearance at steady state includes a non-induced (Day 1) component and an induced component, as estimated by a population PK model.</description>
          <population>PK Population</population>
          <units>Liters per hour (L/hr)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Non-inducible</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="109"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.4" lower_limit="17.6" upper_limit="21.2"/>
                    <measurement group_id="O2" value="5.07" lower_limit="4.83" upper_limit="5.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inducible</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="53"/>
                    <count group_id="O2" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.0" lower_limit="19.2" upper_limit="20.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part C: Oral Volume of Distribution (V/F) of Dabrafenib and Trametinib</title>
        <description>Oral volume of distribution (V/F) of dabrafenib and trametinib were assessed using a population approach. Oral volume of distribution (V/F) is defined as the apparent volume of distribution in the central compartment.</description>
        <time_frame>Day 15, Week 8, Week 16, Week 24, Week 32, Week 40, and Week 48</time_frame>
        <population>PK Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part C: Dabrafenib 150 mg</title>
            <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
          </group>
          <group group_id="O2">
            <title>Part C: Trametinib</title>
            <description>Participants received Trametinib 1 mg or 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part C: Oral Volume of Distribution (V/F) of Dabrafenib and Trametinib</title>
          <description>Oral volume of distribution (V/F) of dabrafenib and trametinib were assessed using a population approach. Oral volume of distribution (V/F) is defined as the apparent volume of distribution in the central compartment.</description>
          <population>PK Population</population>
          <units>Liters (L)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="53"/>
                <count group_id="O2" value="109"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="80.8" lower_limit="73.9" upper_limit="87.7"/>
                    <measurement group_id="O2" value="184" lower_limit="158" upper_limit="210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part D: Cmax of Dabrafenib Metabolites</title>
        <description>The maximum concentration (Cmax) of dabrafenib metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
        <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Cmax of Dabrafenib Metabolites</title>
          <description>The maximum concentration (Cmax) of dabrafenib metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
          <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2285403, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="525" lower_limit="429" upper_limit="643"/>
                    <measurement group_id="O2" value="1055" lower_limit="705" upper_limit="1579"/>
                    <measurement group_id="O3" value="597" lower_limit="474" upper_limit="752"/>
                    <measurement group_id="O4" value="1363" lower_limit="300" upper_limit="2066"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="596" lower_limit="501" upper_limit="709"/>
                    <measurement group_id="O2" value="1203" lower_limit="906" upper_limit="1599"/>
                    <measurement group_id="O3" value="696" lower_limit="551" upper_limit="880"/>
                    <measurement group_id="O4" value="1120" lower_limit="725" upper_limit="1730"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1475" lower_limit="1249" upper_limit="1741"/>
                    <measurement group_id="O2" value="2268" lower_limit="1595" upper_limit="3223"/>
                    <measurement group_id="O3" value="1478" lower_limit="1197" upper_limit="1824"/>
                    <measurement group_id="O4" value="2551" lower_limit="1756" upper_limit="3707"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3637" lower_limit="3119" upper_limit="4242"/>
                    <measurement group_id="O2" value="6743" lower_limit="5133" upper_limit="8859"/>
                    <measurement group_id="O3" value="4158" lower_limit="3136" upper_limit="5514"/>
                    <measurement group_id="O4" value="6319" lower_limit="4725" upper_limit="8450"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50.1" lower_limit="30" upper_limit="84"/>
                    <measurement group_id="O2" value="68.6" lower_limit="36" upper_limit="129"/>
                    <measurement group_id="O3" value="61.2" lower_limit="41" upper_limit="91"/>
                    <measurement group_id="O4" value="86.3" lower_limit="48" upper_limit="155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="210" lower_limit="154" upper_limit="285"/>
                    <measurement group_id="O2" value="355" lower_limit="268" upper_limit="470"/>
                    <measurement group_id="O3" value="289" lower_limit="201" upper_limit="416"/>
                    <measurement group_id="O4" value="440" lower_limit="303" upper_limit="637"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part D: Tmax of Dabrafenib Metabolites</title>
        <description>The time to Cmax (tmax) of DAB metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measuered at Day 1 and Day 21.</description>
        <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Tmax of Dabrafenib Metabolites</title>
          <description>The time to Cmax (tmax) of DAB metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measuered at Day 1 and Day 21.</description>
          <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2285403, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.00" lower_limit="1.50" upper_limit="4.00"/>
                    <measurement group_id="O2" value="3.51" lower_limit="2.00" upper_limit="6.18"/>
                    <measurement group_id="O3" value="3.00" lower_limit="2.00" upper_limit="6.02"/>
                    <measurement group_id="O4" value="2.07" lower_limit="1.50" upper_limit="10.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.00" lower_limit="1.50" upper_limit="3.00"/>
                    <measurement group_id="O2" value="2.00" lower_limit="1.42" upper_limit="3.00"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.47" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.00" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" lower_limit="5.98" upper_limit="10.1"/>
                    <measurement group_id="O2" value="8.93" lower_limit="4.00" upper_limit="24.0"/>
                    <measurement group_id="O3" value="10.0" lower_limit="6.00" upper_limit="24.0"/>
                    <measurement group_id="O4" value="8.00" lower_limit="4.07" upper_limit="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.00" lower_limit="3.00" upper_limit="8.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="3.00" upper_limit="6.00"/>
                    <measurement group_id="O3" value="5.98" lower_limit="2.00" upper_limit="10.00"/>
                    <measurement group_id="O4" value="4.00" lower_limit="3.00" upper_limit="6.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.0" lower_limit="8.00" upper_limit="24.1"/>
                    <measurement group_id="O2" value="24.0" lower_limit="6.00" upper_limit="24.6"/>
                    <measurement group_id="O3" value="24.0" lower_limit="23.5" upper_limit="25.0"/>
                    <measurement group_id="O4" value="24.0" lower_limit="10.0" upper_limit="24.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.75" lower_limit="0" upper_limit="10.0"/>
                    <measurement group_id="O2" value="2.00" lower_limit="0.50" upper_limit="10.0"/>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="10.00"/>
                    <measurement group_id="O4" value="1.75" lower_limit="0" upper_limit="9.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part D: Area Under the Concentration-time Curve (AUC) of Dabrafenib Metabolites</title>
        <description>Area under the concentration-time curve (AUC) from pre-dose to dosing interval (AUC[0-tau]), from pre-dose to the last time of quantifable concentration (AUC[0-tau]), and from pre-dose extrapolated to infinity (AUC[0-inf]) of DAB metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
        <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Area Under the Concentration-time Curve (AUC) of Dabrafenib Metabolites</title>
          <description>Area under the concentration-time curve (AUC) from pre-dose to dosing interval (AUC[0-tau]), from pre-dose to the last time of quantifable concentration (AUC[0-tau]), and from pre-dose extrapolated to infinity (AUC[0-inf]) of DAB metabolites hydroxy-dabrafenib (GSK2285403), carboxy-dabrafenib (GSK2298683) and desmethyl-dabrafenib (GSK2167542) after single and repeat doses of DAB alone and in combination with trametinib was measured at Day 1 and Day 21.</description>
          <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
          <units>ng*hr/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="14"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>GSK2285403, AUC(0-tau), Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3134" lower_limit="2533" upper_limit="3877"/>
                    <measurement group_id="O2" value="5950" lower_limit="4045" upper_limit="8753"/>
                    <measurement group_id="O3" value="3694" lower_limit="2903" upper_limit="4700"/>
                    <measurement group_id="O4" value="6524" lower_limit="4520" upper_limit="9416"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403, AUC(0-inf), Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3963" lower_limit="3147" upper_limit="4990"/>
                    <measurement group_id="O2" value="7415" lower_limit="4991" upper_limit="11015"/>
                    <measurement group_id="O3" value="5026" lower_limit="3934" upper_limit="6422"/>
                    <measurement group_id="O4" value="7907" lower_limit="5434" upper_limit="11506"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2285403, AUC (0-tau), Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2568" lower_limit="2099" upper_limit="3143"/>
                    <measurement group_id="O2" value="4262" lower_limit="3007" upper_limit="6040"/>
                    <measurement group_id="O3" value="2919" lower_limit="2296" upper_limit="3711"/>
                    <measurement group_id="O4" value="4216" lower_limit="2986" upper_limit="5951"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, AUC, (0-tau), Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10396" lower_limit="8388" upper_limit="12885"/>
                    <measurement group_id="O2" value="15952" lower_limit="10532" upper_limit="24160"/>
                    <measurement group_id="O3" value="9575" lower_limit="7143" upper_limit="12835"/>
                    <measurement group_id="O4" value="20935" lower_limit="12430" upper_limit="35259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, AUC (0-t), Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20047" lower_limit="15384" upper_limit="26125"/>
                    <measurement group_id="O2" value="35206" lower_limit="24970" upper_limit="49639"/>
                    <measurement group_id="O3" value="22692" lower_limit="18398" upper_limit="27988"/>
                    <measurement group_id="O4" value="31666" lower_limit="18474" upper_limit="54277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2298683, AUC (0-tau), Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34283" lower_limit="29189" upper_limit="40266"/>
                    <measurement group_id="O2" value="59340" lower_limit="44595" upper_limit="78960"/>
                    <measurement group_id="O3" value="39672" lower_limit="29504" upper_limit="53343"/>
                    <measurement group_id="O4" value="52712" lower_limit="40084" upper_limit="69318"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, AUC(0-tau), Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="132" lower_limit="79" upper_limit="219"/>
                    <measurement group_id="O2" value="190" lower_limit="101" upper_limit="356"/>
                    <measurement group_id="O3" value="88.8" lower_limit="56" upper_limit="139"/>
                    <measurement group_id="O4" value="354" lower_limit="228" upper_limit="549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, AUC(0-t) Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="500" lower_limit="271" upper_limit="925"/>
                    <measurement group_id="O2" value="737" lower_limit="385" upper_limit="1410"/>
                    <measurement group_id="O3" value="614" lower_limit="415" upper_limit="906"/>
                    <measurement group_id="O4" value="1316" lower_limit="824" upper_limit="2103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>GSK2167542, AUC(0-tau), Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1775" lower_limit="1225" upper_limit="2570"/>
                    <measurement group_id="O2" value="2707" lower_limit="2106" upper_limit="3481"/>
                    <measurement group_id="O3" value="2508" lower_limit="1793" upper_limit="3507"/>
                    <measurement group_id="O4" value="3632" lower_limit="2529" upper_limit="5216"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part D: Cmax Assessment of Trametinib</title>
        <description>Cmax of trametinib after single and repeat dose in combination with DAB was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, Cmax was not analyzed in these participants at Days 1 and 21.</description>
        <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Cmax Assessment of Trametinib</title>
          <description>Cmax of trametinib after single and repeat dose in combination with DAB was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, Cmax was not analyzed in these participants at Days 1 and 21.</description>
          <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
          <units>ng/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="6.8" lower_limit="5" upper_limit="10"/>
                    <measurement group_id="O4" value="6.6" lower_limit="4" upper_limit="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="24.1" lower_limit="20" upper_limit="29"/>
                    <measurement group_id="O4" value="22.6" lower_limit="20" upper_limit="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part D: Tmax Assessment of Trametinib</title>
        <description>The tmax of trametinib after single and repeat dose in combination with dabrafenib (DAB) was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, tmax was not analyzed in these participants at Days 1 and 21.</description>
        <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Tmax Assessment of Trametinib</title>
          <description>The tmax of trametinib after single and repeat dose in combination with dabrafenib (DAB) was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, tmax was not analyzed in these participants at Days 1 and 21.</description>
          <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
          <units>Hours</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="3.00"/>
                    <measurement group_id="O4" value="1.50" lower_limit="1.00" upper_limit="8.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="2.00" lower_limit="1.00" upper_limit="4.00"/>
                    <measurement group_id="O4" value="2.00" lower_limit="1.50" upper_limit="3.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part D: Area Under the Concentration-time Curve Assessment of Trametinib</title>
        <description>AUC(0-tau) after single and repeat dose of teametinib alone and in combination with dabrafenib was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, AUC(0-tau) was not analyzed in these participants at Days 1 and 21.</description>
        <time_frame>Day 1: pre-dose, and 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10, and 24 hours post dose. Day 21: pre-dose and 0.5, 1, 1.5, 2, 3, 4, 6, 8, and 10 hours post-dose</time_frame>
        <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Area Under the Concentration-time Curve Assessment of Trametinib</title>
          <description>AUC(0-tau) after single and repeat dose of teametinib alone and in combination with dabrafenib was observed at Day 1 and Day 21. Blood samples for PK analysis of dabrafenib were obtained at pre-dose Day 1 and Day 21 pre-dose and at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours (Day 1 only) post-dose administration. From the plasma concentration-time curve, the PK parameter tmax was determined by standard non-compartmental analysis using WinNonlin.Participants receiving DAB 75 mg to DAB 75 mg + Trametinib 2 mg and those receiving DAB 150 mg to DAB 150 mg + Trametinib 2 mg did not receive Trametinib until Day 29; therefore, AUC(0-tau) was not analyzed in these participants at Days 1 and 21.</description>
          <population>PK Population. Only participants who were available at the indicated timepoints were analyzed.</population>
          <units>ng*h/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 1</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="53.4" lower_limit="40" upper_limit="72"/>
                    <measurement group_id="O4" value="50.7" lower_limit="39" upper_limit="66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 21</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O3" value="366" lower_limit="305" upper_limit="439"/>
                    <measurement group_id="O4" value="356" lower_limit="318" upper_limit="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part D: Number of Participants With the Best Overall Response as Assessed by the Investigator in Participants</title>
        <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 milimeter [mm] in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). To be assigned a status of PR or CR, a confirmatory disease assessment should be performed no less than 28 days after the criteria for response are first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.</description>
        <time_frame>From the date of first dose of study medication to the first documented evidence of a confirmed complete response or partial response (up to approximately 7 years)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Number of Participants With the Best Overall Response as Assessed by the Investigator in Participants</title>
          <description>Best overall response is defined as complete response (CR: the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 milimeter [mm] in the short axis.) or partial reponse (PR: at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]). To be assigned a status of PR or CR, a confirmatory disease assessment should be performed no less than 28 days after the criteria for response are first met. Response was evaluated by an investigator as per Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1.</description>
          <population>ITT Population</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="5"/>
                    <measurement group_id="O4" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>PR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="28"/>
                    <measurement group_id="O4" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part D: Duration of Response as Assessed by the Investigator</title>
        <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
        <time_frame>First documented evidence of PR or CR until the earlier of date of disease progression or date of death due to any cause (up to approximately 7 years)</time_frame>
        <population>ITT Population. Only those participants who had CR or PR were considered.</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Duration of Response as Assessed by the Investigator</title>
          <description>Duration of response for participants with either a CR (the disappearance of all target lesions. Any pathological lymph nodes must be &lt;10 mm in the short axis.) or PR (at least a 30% decrease in the sum of the diameters of target lesions, taking as a reference, the Baseline sum of the diameters [e.g., percent change from Baseline]) is defined as the time from the first documented evidence of a PR or CR until the first documented sign of disease progression (PD) or death due to any cause. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
          <population>ITT Population. Only those participants who had CR or PR were considered.</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.2" lower_limit="3.5" upper_limit="14.8"/>
                    <measurement group_id="O2" value="10.1" lower_limit="5.6" upper_limit="NA">NA: Not estimable due to insufficient number of participants with events</measurement>
                    <measurement group_id="O3" value="5.9" lower_limit="3.7" upper_limit="9.0"/>
                    <measurement group_id="O4" value="14.3" lower_limit="8.8" upper_limit="67.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part D: Progression-free Survival (PFS) as Assessed by the Investigator</title>
        <description>PFS is defined as the interval between the date of randomization and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
        <time_frame>From the date of randomization to the earliest date of disease progression (PD) or death due to any cause (up to approximately 7 years)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Progression-free Survival (PFS) as Assessed by the Investigator</title>
          <description>PFS is defined as the interval between the date of randomization and the earliest date of PD or death due to any cause. PD was based on radiographic or photographic evidence, and assessments were made by the investigator according to RECIST, version 1.1. PD is defined as at least a 20% increase in the sum of the diameters of target lesions, taking as a reference, the smallest sum of diameters recorded since the treatment started (e.g., percent change from nadir, where nadir is defined as the smallest sum of diameters recorded since treatment start). In addition, the sum must have an absolute increase from nadir of 5 mm.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.9" lower_limit="3.4" upper_limit="11.4"/>
                    <measurement group_id="O2" value="9.3" lower_limit="3.7" upper_limit="28.6"/>
                    <measurement group_id="O3" value="7.4" lower_limit="5.6" upper_limit="10.7"/>
                    <measurement group_id="O4" value="11.1" lower_limit="7.0" upper_limit="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Part D: Overall Survival (OS)</title>
        <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact.</description>
        <time_frame>From the date of first dose until date of death due to any cause (up to approximately 7 years)</time_frame>
        <population>ITT Population</population>
        <group_list>
          <group group_id="O1">
            <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O2">
            <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
          </group>
          <group group_id="O3">
            <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
          <group group_id="O4">
            <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
            <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
          </group>
        </group_list>
        <measure>
          <title>Part D: Overall Survival (OS)</title>
          <description>OS is defined as the interval of time between the date of randomization until the date of death due to any cause. For the participants who did not die, overall survival was censored at the date of last contact.</description>
          <population>ITT Population</population>
          <units>Months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="12"/>
                <count group_id="O2" value="16"/>
                <count group_id="O3" value="43"/>
                <count group_id="O4" value="39"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" lower_limit="12.4" upper_limit="28.0"/>
                    <measurement group_id="O2" value="15.5" lower_limit="10.4" upper_limit="60.0"/>
                    <measurement group_id="O3" value="15.3" lower_limit="13.0" upper_limit="37.2"/>
                    <measurement group_id="O4" value="40.3" lower_limit="15.7" upper_limit="69.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse Events and Serious Adverse Events were collected for the maximum actual duration of treatment exposure and follow up for a participant per the protocol for approximately 90 months.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Part A: Dabrafenib 75 mg + Trametinib 2 mg</title>
          <description>Participants received a single dose of dabrafenib 75 mg gelatin capsules with repeat dose trametinib (Day 15).</description>
        </group>
        <group group_id="E2">
          <title>Part B: Dabrafenib 75 mg + Trametinib 1 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 75 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available pharmacokinetic (PK), safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on dose-limiting toxicities (DLTs) occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="E3">
          <title>Part B: Dabrafenib 150 mg + Trametinib 1 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors and participants who had salivary ductal cancer received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="E4">
          <title>Part B: Dabrafenib 150 mg + Trametinib 1.5 mg</title>
          <description>Melanoma BRAF-positive participants who did not receive prior treatment with BRAF inhibitors received dabrafenib 150 mg gelatin capsules BID and trametinib 1.5 mg tablets QD as continuous daily dosing. Dose escalation decisions were made based on all available PK, safety, and other data from the first 4 evaluable participants, and additional participants were enrolled based on DLTs occurring during the first 3 weeks of treatment.</description>
        </group>
        <group group_id="E5">
          <title>Part B: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Melanoma BRAF-positive participants who received prior treatment with BRAF inhibitors and participants who had colorectal cancer and BRAFi naïve melanoma received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD as continuous daily dosing. Dose escalation did not proceed beyond these doses of dabrafenib and trametinib.</description>
        </group>
        <group group_id="E6">
          <title>Part C (Randomized): Dabrafenib 150 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID.</description>
        </group>
        <group group_id="E7">
          <title>Part C (Randomized): Dabrafenib 150 mg + Trametinib 1 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 1 mg tablets QD.</description>
        </group>
        <group group_id="E8">
          <title>Part C (Randomized): Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="E9">
          <title>Part C (Crossover): Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants who received dabrafenib 150 mg capsules BID alone in the Randomized Phase were given the opportunity to receive combination dosing of dabrafenib 150 mg gelatin capsules BID and trametinib 2 mg tablets QD upon disease progression with approval of the GlaxoSmithKline (GSK) Medical Monitor.</description>
        </group>
        <group group_id="E10">
          <title>Part D: Dabrafenib (DAB) 75 mg to DAB 75 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 75 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 75 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
        </group>
        <group group_id="E11">
          <title>Part D: Dabrafenib 150 mg to DAB 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 150 mg HPMC capsules BID. These participants, after completion of serial PK collection in the first treatment period, were allowed to continue with dabrafenib 150 mg BID and trametinib 2 mg tablets QD as combination dosing starting on Day 29.</description>
        </group>
        <group group_id="E12">
          <title>Part D: Dabrafenib 75 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 75 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
        <group group_id="E13">
          <title>Part D: Dabrafenib 150 mg + Trametinib 2 mg</title>
          <description>Participants received dabrefinib 150 mg HPMC capsules BID and trametinib 2 mg tablets QD.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="55" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="39" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="24" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="11" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="29" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="30" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Febrile neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Immune thrombocytopenic purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Atrial thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cardiogenic shock</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Left ventricular dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ventricular arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Addison's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Adrenal insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Chorioretinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Optic ischaemic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Uveitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal wall haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Duodenal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastric ulcer haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Intestinal perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Large intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Obstructive pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="15" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="16" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gallbladder enlargement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergy to immunoglobulin therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bacterial sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cardiac infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Device related sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Endocarditis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hepatic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Kidney infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pelvic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Prostate infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pseudomonal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Streptococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Systemic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wound dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood calcium increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ejection fraction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hepatic enzyme increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>White blood cell count increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pathological fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma pancreas</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Clear cell renal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Colorectal adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Intracranial tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lentigo maligna</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lip squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Malignant ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Metastases to meninges</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Metastases to spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Metastatic squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pericardial neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of head and neck</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma of the tongue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Superficial spreading melanoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tumour haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Brain stem haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cerebrospinal fluid leakage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cervical cord compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chronic inflammatory demyelinating polyradiculoneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Focal dyscognitive seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemorrhage intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Head discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Intracranial pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Multiple sclerosis relapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Parkinson's disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sensory ganglionitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Renal disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Obstructive airways disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Upper airway obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Granulomatous dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Orthostatic hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vena cava thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (21.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="27" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="91" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="53" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="53" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="55" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="44" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="41" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="37" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymph node pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Intracardiac mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Dermoid cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Ear congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenopia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chorioretinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Keratopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lacrimation decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Photopsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Visual impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vitreous detachment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vitreous floaters</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="15" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="26" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="15" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="11" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="27" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="10" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="18" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Large intestine perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mesenteric artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="49" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="30" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="26" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="11" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="10" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="26" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="21" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oral mucosa erosion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Retching</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tongue ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="39" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="23" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="26" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="13" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="20" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="21" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="38" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="24" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="29" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="15" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="13" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Face oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="50" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="22" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="35" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="32" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="29" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gait disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="14" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="10" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="11" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="58" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="13" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="39" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="37" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="7" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="19" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="19" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Systemic inflammatory response syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Xerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Contrast media allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cytokine release syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Anorectal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Periorbital infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="10" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wound infection staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Infusion related reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Spinal compression fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sunburn</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tooth fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wound haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="14" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood iron decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood testosterone decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Carbon dioxide increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="6" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Liver function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphocyte count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mean cell volume decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Platelet count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Thyroxine free decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>White blood cell count decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="23" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="18" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="16" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="14" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypermagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperuricaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypomagnesaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Impaired fasting glucose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lactic acidosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="18" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="28" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="12" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="9" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="8" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="17" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="17" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Limb mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Muscular weakness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="17" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="12" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="16" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="12" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="8" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="13" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pain in jaw</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rhabdomyolysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cancer pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemangioma of skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Juvenile melanoma benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tumour pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ataxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="24" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="7" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysarthria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="32" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="17" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="25" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="9" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="13" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="16" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Motor dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Noninfective encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sedation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="5" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Mood altered</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Thinking abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Renal injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pelvic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="22" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="11" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="10" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="19" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="12" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="7" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="5" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hiccups</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypoxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Laryngeal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="7" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="9" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pulmonary congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Throat irritation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="11" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="12" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="5" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Blister</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="12" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="11" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="6" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="10" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Erythema nodosum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hair texture abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="15" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Keratosis pilaris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Macule</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="16" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="11" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="15" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="8" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="9" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Nodular rash</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Onychoclasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Palmar-plantar erythrodysaesthesia syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="9" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Photodermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="8" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="8" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="8" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="3" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="4" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="7" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="6" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="21" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="19" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="13" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="8" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="6" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="14" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="18" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="2" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="6" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="2" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="5" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="2" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Solar lentigo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="3" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="1" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Transient acantholytic dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="3" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="6" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="1" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="4" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="5" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="4" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="9" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="4" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="7" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="7" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="9" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="3" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="5" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Labile blood pressure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="0" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="4" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="2" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="3" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="0" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="27"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="94"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="53"/>
                <counts group_id="E7" subjects_affected="1" subjects_at_risk="54"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="55"/>
                <counts group_id="E9" subjects_affected="1" subjects_at_risk="45"/>
                <counts group_id="E10" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E11" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E12" subjects_affected="1" subjects_at_risk="41"/>
                <counts group_id="E13" subjects_affected="0" subjects_at_risk="39"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial or disclosure of trial results in their entirety.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>862-778-8300</phone>
      <email>Novartis.email@novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

